SEARCH
Search Details
OGAWA HiroyukiUniversity Hospital / Thoracic SurgeryAssistant Professor
Research activity information
■ Award■ Paper
- BACKGROUND: Lung squamous cell carcinoma (LUSC) lacks well-defined molecular targets. This study investigated the clinical and biological relevance of POU class 2 homeobox 3 (POU2F3), a tuft cell-associated transcription factor, in LUSC. METHODS: RNA sequencing data of patients with LUSC from The Cancer Genome Atlas (TCGA cohort, n = 190) was analysed and compared to a cohort of surgically resected cases analyzed via immunohistochemistry (IHC cohort, n = 137). Prognostic impact was assessed via survival analyses. Transcriptomic features, pathway enrichment, and immune profiles were evaluated via differentially expressed gene analysis, Gene Set Enrichment Analysis, and CIBERSORTx. RESULTS: High POU2F3 expression independently predicted poor overall survival in the TCGA cohort (HR = 2.06, 95% CI: 1.04-4.08, P = 0.039). In contrast, POU2F3 expression was not prognostic in the IHC cohort (P = 0.995). Morphologically, POU2F3-positive tumours were enriched for non-keratinizing and poorly differentiated subtypes. Transcriptomic analysis showed suppression of proliferation and immune-related pathways (FDR < 0.001), with suggestive enrichment of the TGF-β (FDR = 0.143) and p53 (FDR = 0.229) signaling pathways. On immune deconvolution, POU2F3-high tumours showed a nominal increase in activated dendritic cells, which did not withstand multiple testing correction. POU2F3 protein was detected in 12.4% of tumours and was significantly associated with p53 or RB1 abnormalities (single or double) (P = 0.028). CONCLUSIONS: POU2F3 marks a transcriptionally distinct, early-stage subtype of LUSC with keratinization-related features. Its prognostic relevance appears context-dependent and requires prospective validation in uniformly treated cohorts.May 2026, Japanese journal of clinical oncology, English, International magazineScientific journal
- BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is used for clinical diagnosis and staging in lung cancer (LC) patients. However, establishing patient-derived preclinical models using needle biopsy samples remains challenging. This study describes the establishment and utility of patient-derived organoid (PDO) from EBUS specimens and EBUS patient-derived xenograft (PDX). METHODS: Total of 175 EBUS specimens were used to establish PDO and PDX, respectively. "Stable establishment" organoids with passage numbers ≥10 were used for genomic, transcriptome and pathological assessment. Drug sensitivity of EBUS organoids and PDX tumors were compared with those of the matched patient. Drug screening was performed using stably established organoid models. RESULTS: We successfully established a total of twenty EBUS organoids: six EBUS-PDOs and fourteen EBUS-xenograft derived organoids (XDO). These stable cancer organoid models were validated for cancer cell enrichment and pathological assessment. Pathological findings, exome and transcriptome analysis showed a high correlation between EBUS organoids and parental samples. EBUS organoids and PDX demonstrated consistent drug response patterns with their corresponding patients. A drug screening conducted on an EBUS organoid led to the discovery of potent activity of trametinib to a rare MAP2K1 K57N mutation. CONCLUSIONS: EBUS-PDO and -XDO are good options to generate stable organoids in advanced stage lung cancer patients. The models were consistent with the genetic and pathological features of patient tumors, as well as the patient's responses to treatment, supporting their utility for novel therapeutic research.Lead, Apr. 2026, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 103893 - 103893, English, International magazine[Refereed]Scientific journal
- Apr. 2026, General thoracic and cardiovascular surgery, English, Domestic magazine[Refereed]Scientific journal
- BACKGROUND: While early lung cancers are increasingly managed with sublobar resection, inadequate surgical margin (SM) is still a major concern, increasing the risk of locoregional recurrence. In this study, we evaluated the feasibility of using computed tomography (CT) as an intraoperative SM guidance tool by comparing with histopathologic SM measurement. METHODS: Patients scheduled for segmentectomy or wedge resection were enrolled. Immediately after resection, lung samples were reinflated and CT images were acquired. SM length, defined as the distance between the tumor and staple line, was measured by both CT and pathology. CT-derived SM length was compared with pathology-derived SM length using Bland-Altman analysis. Factors affecting differences between the 2 measurements were assessed using multiple linear regression analysis. RESULTS: A total of 52 resected specimens were analyzed. There were 34 solid (65.4%) and 18 subsolid tumors (34.6%). The mean SM length by CT and pathology was 11.3 mm and 10.1 mm, respectively. There was overall a 10.6% reduction from CT to pathology (P = .033). In Brand-Altman analysis, the mean difference between SM on CT and pathology was 1.2 mm, with the 95% limits of agreement from -7.2 to 9.6 mm. The multiple linear regression analysis revealed that subsolid tumors (P = .047) and depth from pleura (P < .01) were independent factors affecting SM discrepancy. CONCLUSIONS: SM measurement by CT is feasible and has the potential to aid in the evaluation of SM intraoperatively. However, surgeons must anticipate the potentially greater discordance when using this technique for subsolid tumors.Mar. 2026, The Annals of thoracic surgery, 121(3) (3), 654 - 661, English, International magazine[Refereed]Scientific journal
- OBJECTIVES: Previous studies reported worse outcomes for radiographically central tumors, but the impact of pathologically confirmed tumor origin remains unclear. This study investigated whether pathologically determined inner lesions are associated with nodal upstaging and poorer prognosis than outer lesions, and examined segmentectomy feasibility versus lobectomy. METHODS: We retrospectively analyzed participants with clinical stage IA (Union for International Cancer Control version 8) non-small cell lung cancer who underwent segmentectomy and lobectomy between November 2007 and December 2022 at 2 Japanese centers. The location of the tumor origin was confirmed pathologically via the Walter classification. Tumors classified as central and intermediate were allocated to the inner group, whereas those classified as peripheral type were allocated to the outer group. The oncologic outcomes were compared between the 2 groups. After propensity score matching analysis on the basis of sex, age, pulmonary function, serum carcinoembryonic antigen level, and radiographic findings, we compared oncologic outcomes in patients who underwent segmentectomy (n = 99) and lobectomy (n = 99) in the inner group. RESULTS: The cohort comprised inner (n = 654) and outer (n = 1275) groups. Nodal upstaging was greater in the inner group (13.1% [86/654] vs 9.5% [121/1275], P = .015). Five-year recurrence-free survival (RFS) was lower in the inner group (73.1%; 95% CI, 69.4%-77.3% vs 79.4%; 95% CI, 76.7%-81.8%, P = .002). Multivariable analysis did not identify segmentectomy as significant for RFS (hazard ratio, 0.81; 95% CI, 0.58-1.13; P = .20). In matched inner lesions, segmentectomy and lobectomy showed similar RFS (83.6%; 95% CI, 76.3-93.1% vs 76.4%; 95% CI, 66.8-87.4%; P = .80). CONCLUSIONS: Although worse prognosis and increased nodal upstaging should be considered in inner primary tumors, segmentectomy is an acceptable treatment option compared with lobectomy for pathologically confirmed inner-located early-stage NSCLC.Feb. 2026, JTCVS open, 29, 101575 - 101575, English, International magazine[Refereed]Scientific journal
- BACKGROUND: Interstitial lung disease (ILD) and lung cancer are often associated, and ILD-associated lung cancer is a difficult condition to treat. Radiotherapy (RTx) is one of a standard therapeutic modalities for lung cancer, but pre-existing ILD is known to be a significant risk factor for developing severe radiation pneumonitis (RP) after treatment. In this context, there is a demand for alternative treatment modalities for ILD-associated localized lung cancer. Photodynamic therapy (PDT) is a minimally invasive treatment modality for lung cancer that can be performed endoscopically. In this study, we investigated proof-of-concept animal studies comparing RTx vs. PDT for (I) anti-tumor effects in a mouse xenograft model; and (II) pulmonary toxicity in a rat ILD model. METHODS: For the mouse tumor study, NCr-Foxn1nu athymic mice were subcutaneously inoculated with A549 or H460 human lung cancer cells to unilateral thigh and followed for growth until 8-12 mm sized. Ultrasmall nanostructured nanoparticle porphylipoprotein (PLP) was used in this study. The mice were divided into three intervention groups; control, RTx, and PDT. RTx group received a single 20 Gy local irradiation, while PDT group received an intravenous PLP (4 mg/kg) 24 hours before treatment, followed by laser ablation (671 nm) at 100 J/cm2. For the rat ILD study, Sprague-Dawley immunocompetent rats were given an intratracheal single dose of bleomycin (BLM; 2 mg/kg) or vehicle control, and were followed up for 3 weeks to develop ILD. RTx group received a single 20 Gy irradiation, while PDT group had PLP administration (4 mg/kg), laser fiber delivered to the left lung base under computed tomography (CT) guidance with mechanical ventilation support and PDT performed at 100 J/cm2. Chest CT was evaluated monthly and an autopsy was done after 1- or 3-month follow-up. RESULTS: In the mouse xenograft model, PLP biodistribution showed the best tumor-to-contralateral background muscle ratio at 24 hours post-injection. In day 7, both RTx and PDT showed a significant tumor volume difference in A549 and H460 xenografts over control, while PDT showed a significant tumor volume difference in A549 xenograft compared to RTx. In rat ILD model, chest CT showed that BLM + RTx exhibited increased lung infiltrates at week 15 compared to BLM + PDT. Leukocyte cell fractionation of bronchoalveolar lavage at 15 weeks showed that BLM + RTx had significantly higher cell counts than BLM + PDT or control in total leukocyte, neutrophil, and macrophage. In Ashcroft's lung fibrosis pathology score, BLM + RTx showed more significant score increases over control, BLM, or BLM + PDT. CONCLUSIONS: Despite the differences in dose delivery between RTx and PDT, PDT demonstrated comparable antitumor efficacy to RTx in mouse xenograft model and a safer pulmonary toxicity profile than RTx in rat ILD model. PDT is possibly a promising treatment modality for lung cancer associated with ILD.Dec. 2025, Translational lung cancer research, 14(12) (12), 5323 - 5334, English, International magazine[Refereed]Scientific journal
- BACKGROUND: There is a significant unmet clinical need for accurate target identification in diagnosis and treatment of malignant tumors, including lung cancer. Optical imaging, specifically fluorescence-based, enables real-time tracking during endoscopic or surgical procedures. Here, we aim to investigate the scenario in which the fluorescence signal is possibly not due to the presence of the administered fluorescent agent, using a preclinical transbronchial lung cancer model. METHODS: Pafolacianine is a folate analog conjugated with an indocyanine green-like dye (peak excitation 774-776 nm, detection 794-796 nm). A composite optical fiberscope (COF) with 0.97 mm outer diameter tip was used for laser excitation at 776 nm and imaging. Spectrometer measurements along the same optical axis as the COF were also made to characterize the signal. In a mouse xenograft model, human folate receptor-positive KB tumor cells were inoculated subcutaneously into the flank of immunodeficient (NCr-Foxn1nu) mice and grown to 8-15 mm diameter. The mice were then infused with 0.025 or 0.25 mg/kg pafolacianine or negative control. At 24 hours after infusion, tumor and contralateral background spectral measurements were acquired using both the COF imaging system and the spectrometer. In a swine peribronchial model, a pafolacianine-infused tumor was placed manually on the outer wall of the swine bronchus by forceps. The COF was inserted into the working channel of a bronchoscope, which was then inserted through an endotracheal tube and navigated close to where the tumor was located. While changing the distance from the COF tip to the bronchial mucosa, transbronchial COF imaging and spectroscopic measurements were acquired separately. RESULTS: In the in vivo mouse xenograft model, we observed a peak in the spectrometer spectrum at 810 nm that was more intense in the 0.25 mg/kg cohort than in the 0.025 mg/kg pafolacianine cohort. In the swine peribronchial tumor model with negative control tumor, we observed the excitation laser signal (776 nm) with the spectrometer when the COF tip was placed in very close (~1 mm) proximity to the bronchial mucosa but this signal was not detected at 5 or 10 mm distance. CONCLUSIONS: In situations of very close proximity of the COF to the bronchial wall (~1 mm), we detected both excitation and emission signals. When the distance was increased slightly, only the fluorescence emission signal was detected. Although these results are not fully generalizable to all fluorescence bronchoscopy settings, it is important for clinicians to be aware of possible limitations in the filter rejection of excitation light leakage and to avoid extreme proximity between the bronchial mucosa and the fiber tip. We report this to exemplify artefacts that can occur in fluorescence bronchoscopy.Nov. 2025, Translational lung cancer research, 14(11) (11), 4896 - 4905, English, International magazine[Refereed]Scientific journal
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 529 - 529, Japanese
- (NPO)日本肺癌学会, Oct. 2025, 肺癌, 65(6) (6), 988 - 988, Japanese
- OBJECTIVES: Intimal sarcoma is a rare vascular malignancy with a poor prognosis and no established treatment. This study aimed to identify clinicopathological and transcriptomic factors associated with disease progression to uncover potential therapeutic targets. METHODS: Ten patients with surgically resected intimal sarcoma were included. Ribonucleic acid (RNA) sequencing was performed on formalin-fixed, paraffin-embedded tumour samples, of which 8 passed quality control. Patients were stratified by the median overall survival of 17 months. Differentially expressed genes (DEGs) were identified and analysed using Gene Ontology (GO), Enrichr, and Gene Set Enrichment Analysis (GSEA). Immunohistochemistry was used to validate selected protein expression. RESULTS: The primary tumour site was the pulmonary artery in 8 cases and the heart in 2 cases. The median survival was 17 months, with a 5-year survival rate of 13.3%. Twenty-eight DEGs (|logFC| > 2, P < 0.01) were identified, most of which were upregulated in poor-prognosis tumours. GO and Enrichr analyses revealed enrichment in ribosome-related processes, including cytoplasmic translation and ribosomal biogenesis. GSEA showed enrichment of MYC targets and oxidative phosphorylation; epithelial-mesenchymal transition was moderately enriched, and myogenesis was downregulated. Immunohistochemistry confirmed overexpression of RPS27 and RPL26 in poor-prognosis tumours. CONCLUSIONS: Transcriptomic analysis revealed upregulation of ribosome-related genes in aggressive intimal sarcoma. Aberrant protein synthesis may contribute to poor prognosis and represent a novel therapeutic vulnerability.Aug. 2025, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 67(8) (8), English, International magazine[Refereed]Scientific journal
- OBJECTIVE: We developed a novel, noninvasive, extended reality-aided marking procedure for tumor localization and aimed to evaluate its feasibility and safety for sublobar resection in minimally invasive surgery. METHODS: We prospectively evaluated the concordance rate between extended reality-aided marking and actual tumor localization for 20 patients who underwent sublobar resection, including wedge resection and segmentectomy. During sublobar resection, the augmented reality image of the 3-dimensional pulmonary anatomy and the tumor were overlaid onto the thoracoscopic monitor. This allowed the surgeons to observe the tumor location with the head-mounted mixed reality display during the surgery. Marking concordance was defined as the difference of 10 mm or less between the distances from the actual tumor margin and the identified marking point on the extended reality to the margin. RESULTS: We enrolled 11 patients who underwent wedge resection and 9 patients who underwent segmentectomy. For each case, the pulmonary anatomy and tumor were successfully overlaid onto the operative image. The median computed tomography tumor size was 13.5 mm (interquartile range, 10.7-21.7 mm). The extended reality-aided marking method accurately delineated 90% of cases (18 of 20). The median distance from the actual surgical margin was 18 mm (interquartile range, 11-23.5 mm). The median duration of surgery was 117 (interquartile range, 64-147) minutes, and the perioperative courses were uneventful for all cases except for paroxysmal atrial fibrillation in 1 patient. CONCLUSIONS: Our novel, noninvasive, extended reality-based marking method is safe and feasible for identifying tumor locations during sublobar resection.Aug. 2025, JTCVS techniques, 32, 157 - 162, English, International magazine[Refereed]Scientific journal
- PURPOSE: This study examined the learning curve of segmentectomy using the "fused surgery" approach. METHODS: We retrospectively collected data from 100 patients who underwent segmentectomy via fused robot-assisted thoracoscopy at our institution between September 2020 and February 2024. The learning curve was evaluated using the cumulative sum of the operative times in all cases and was analyzed separately for simple and complex segmentectomies. RESULTS: After applying the cumulative sum method to all cases, we obtained a graph of the operative time that showed three well-differentiated phases: phase 1 (n = 23), the initial learning phase; phase 2 (n = 28), the increased competence phase; and phase 3 (n = 49), the highest skill phase. Comparing phases 1 and 2 with phase 3, we found significant differences in operative time (P < 0.001); however, no significant differences were observed in bleeding or rate of postoperative complications. We observed a significant reduction in operative time after 25 simple segmentectomies and 22 complex segmentectomies. CONCLUSIONS: The data suggested that the inflection point of the learning curve was achieved in 51 cases. Complex segmentectomy requires the same cases to achieve the same level of competence as simple segmentectomy.Jun. 2025, Surgery today, 55(6) (6), 823 - 829, English, Domestic magazine[Refereed]Scientific journal
- OBJECTIVE: High-grade neuroendocrine carcinoma (HGNEC) with dominant POU2F3 expression exhibits non-neuroendocrine features. However, clinical data regarding this subset of pulmonary HGNECs are scarce, and its clinical characteristics remain unclear. METHODS: Clinicopathological data from 109 patients who underwent surgery for HGNEC were collected and analyzed based on transcription factor expression. Patients were divided into a POU2F3-dominant group (HGNEC-P) and a non-dominant group (HGNEC-non-P) according to immunohistochemical analysis. The clinicopathological characteristics of the two groups were compared, and univariate and multivariate analyses were conducted to identify prognostic factors. RESULTS: The HGNEC-P group comprised 26 patients, while the HGNEC-non-P group comprised 83 patients. The HGNEC-P group showed significantly lower expression of carcinoembryonic antigen (CEA) (p < 0.001) and a lower rate of vascular invasion (p = 0.021) compared to the HGNEC-non-P group. In addition, the HGNEC-P group exhibited a unique tumor marker profile, with lower serum CEA and higher serum cytokeratin antigen (CYFRA) levels (p < 0.001 and p = 0.046, respectively). Complete resection was achieved in all HGNEC-P cases, whereas only 75.9% of HGNEC-non-P cases achieved complete resection. Multivariate analysis identified POU2F3 expression as an independent prognostic factor for recurrence-free survival (RFS) and disease-specific survival (DSS) (p = 0.037 and p = 0.038, respectively). In patients with pathological Stage I disease, the HGNEC-P group showed significantly better RFS (p = 0.010). CONCLUSIONS: POU2F3-dominant HGNEC is associated with distinct clinicopathological features and favorable prognosis, particularly in early-stage disease. These findings may support the identification of this subset and inform the development of more effective treatment strategies.Apr. 2025, Cureus, 17(4) (4), e82758, English, International magazine[Refereed]Scientific journal
- Blood oozing from the access port due to breakage of the wound protector may obscure the surgical view during thoracoscopic surgery. Therefore, we developed a novel wound protector with honeycomb meshing that prevents its breakage by dispersing the force acting on the edge of the access port in six directions. This novel wound protector could reduce the likelihood of interruption during surgery due to blood oozing from the surface of the access port, contributing to surgical efficacy and safety.2025, Asian journal of endoscopic surgery, 18(1) (1), e70150, English, Domestic magazine[Refereed]Scientific journal
- OBJECTIVES: Computed tomography (CT) imaging of a sublobar resection specimen may inform intraoperative surgical margin assessment. However, consistency with final pathological margins has not been previously evaluated. In this study, we investigated the concordance between surgical margin measurements by CT versus pathology measurements using an ex vivo sublobar lung resection model. METHODS: Pig lung wedge samples containing agarose pseudotumours were harvested. CT images were acquired following specimen inflation. The specimen was bisected along the same plane observed by CT for accurate comparison with pathological surgical margin measurement. The bisected samples were then fixed in formalin before preparing haematoxylin & eosin slides. Surgical margin length at four distinct stages (CT, gross pre-formalin fixation, gross post-formalin fixation and pathology) were measured and compared. RESULTS: A total of 50 lung specimens were analysed. After specimen processing, Surgical margin length decreased in 94% (47/50) and increased in 6% (3/50) of samples. Mean surgical margin lengths were as follows: CT 14.0 mm (range: 4.5-28.3 mm), gross pre-formalin fixation 13.0 mm (range: 4.0-25.0 mm), gross post-formalin fixation 12.1 mm (range: 2.5-26.0 mm) and pathology 10.9 mm (range: 1.0-23.4 mm). There was an average -23.8% (range: +11 to -82%) change in surgical margin length from CT to final pathology (P < 0.001). CONCLUSIONS: While CT-based surgical margin measurement is feasible, we observed an average 23.8% discordance when compared to final pathology measurement. Surgeons must be aware that the CT-derived surgical margin generally overestimates the pathology-derived surgical margin.Dec. 2024, Interdisciplinary cardiovascular and thoracic surgery, 40(1) (1), English, International magazine[Refereed]Scientific journal
- Patient-derived xenografts (PDXs) are increasingly utilized in preclinical drug efficacy studies due to their ability to retain the molecular, histological, and drug response characteristics of patient tumors. This study aimed to investigate the factors influencing the successful engraftment of PDXs. Lung adenocarcinoma PDXs were established using freshly resected tumor tissues obtained through surgery. Radiological data of pulmonary nodules from this PDX cohort were analyzed, categorizing them into solid tumors and tumors with ground-glass opacity (GGO) based on preoperative CT images. Gene mutation status was obtained from next generation sequencing data and MassARRAY panel. A total of 254 resected primary lung adenocarcinomas were utilized for PDX establishment, with successful initial engraftment in 58 cases (22.8 %); stable engraftment defined as at least three serial passages was observed in 43 cases (16.9 %). The stable engraftment rates of PDXs from solid tumors and tumors with GGO were 22.1 % (42 of 190 cases) and 1.6 % (1 of 64 cases), respectively (P < 0.001). Adenocarcinomas with advanced stage, poor differentiation, solid histologic subtype, and KRAS or TP53 gene mutations were associated with stable PDX engraftment. Avoiding tumors with GGO features could enhance the cost-effectiveness of establishing PDX models from early-stage resected lung adenocarcinomas.Lead, Aug. 2024, Lung cancer (Amsterdam, Netherlands), 194, 107863 - 107863, English, International magazine[Refereed]Scientific journal
- OBJECTIVE: Endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) may effectively treat acute pulmonary embolisms (PEs). Here, we assessed the effectiveness of clot dissolution and safety of tissue plasminogen activator (t-PA) injection using EBUS-TBNI in a 1-week survival study of a porcine PE model. METHODS: Six pigs with bilateral PEs were used: 3 for t-PA injection using EBUS-TBNI (TBNI group) and 3 for systemic administration of t-PA (systemic group). Once bilateral PEs were created, each 25 mg of t-PA injection using EBUS-TBNI for bilateral PEs (a total of 50 mg t-PA) and 100 mg of t-PA systemic administration was performed on day 1. Hemodynamic parameters, blood tests, and contrast-enhanced computed tomography scans were carried out at several time points. On day 7, pigs were humanely killed to evaluate the residual clot volume in the pulmonary arteries. RESULTS: The average of percent change of residual clot volumes was significantly lower in the TBNI group than in the systemic group (%: systemic group 36.6 ± 22.6 vs TBNI group 9.6 ± 6.1, P < .01) on day 3. Considering the elapsed time, the average decrease of clot volume per hour at pre-t-PA to post t-PA was significantly greater in the TBNI group than in the systemic group (mm3/hour: systemic 68.1 ± 68.1 vs TBNI 256.8 ± 148.1, P < .05). No hemorrhage was observed intracranially, intrathoracically, or intraperitoneally on any contrast-enhanced computed tomography images. CONCLUSIONS: This study revealed that t-PA injection using EBUS-TBNI is an effective and safe way to dissolve clots.Dec. 2023, JTCVS techniques, 22, 292 - 304, English, International magazine[Refereed]Scientific journal
- OBJECTIVE: Lung sentinel lymph node mapping, where peritumorally injected material is tracked through the lymphatics, aims to find the first potential sites of nodal metastasis. We sought to evaluate the preclinical feasibility of bronchoscopic fluorescence-guided sentinel lymph node mapping. METHODS: Healthy Yorkshire pigs were used; sentinel lymph node mapping was performed with indocyanine green. The primary fluorescence imaging method was an ultrathin composite fiberscope placed in the bronchoscope working channel. Secondary methods used a fluorescence thoracoscope placed in the trachea (rigid bronchoscopy) and pretracheal fascial plane (mediastinoscopy) to validate ultrathin composite fiberscope settings for sentinel lymph node detection. A tracheostomy was created, and the pig was placed in a lateral decubitus position. Transbronchial intraparenchymal indocyanine green injection was performed primarily in the right lower lobe. Ultrathin composite fiberscope and rigid bronchoscopy were performed with (n = 6) or without (n = 2) mediastinoscopy, with the former group guiding dose and ultrathin composite fiberscope optimization. Fluorescent targets were interrogated by endobronchial ultrasound before ultrathin composite fiberscope-guided transbronchial needle aspiration. Specimen fluorescence was documented before creating cytological smears. Pigs were killed postprocedure for nodal dissection. RESULTS: A total of 100 μL of 10 mg/mL indocyanine green generated strong transbronchial fluorescence with low risk of indocyanine green contamination. Fluorescence was detectable by 10 minutes postinjection. There was concordance among ultrathin composite fiberscope, rigid bronchoscopy, and mediastinoscopy. Except for 1 pig with airway contamination, ultrathin composite fiberscope-guided endobronchial ultrasound transbronchial needle aspiration obtained fluorescent material in all pigs. Specimen fluorescence was associated with specimen adequacy. CONCLUSIONS: Bronchoscopic fluorescence-guided sentinel lymph node mapping was feasible, with specimen fluorescence providing real-time feedback on sentinel lymph node biopsy success. If translated to clinical practice, attention must be paid to minimizing indocyanine green leakage.Jan. 2023, The Journal of thoracic and cardiovascular surgery, 165(1) (1), 337 - 350, English, International magazine[Refereed]Scientific journal
- In combination with immune checkpoint inhibitors, photodynamic therapy can induce robust immune responses capable of preventing local tumor recurrence and delaying the growth of distant, untreated disease (ie. the abscopal effect). Previously, we found that repeated photodynamic therapy (R-PDT) using porphyrin lipoprotein (PLP) as a photosensitizer, without the addition of an immune checkpoint inhibitor, can induce the abscopal effect. To understand why PLP mediated R-PDT alone can induce the abscopal effect, and how the addition of an immune checkpoint inhibitor can further strengthen the abscopal effect, we investigated the broader immune mechanisms facilitated by R-PDT and combination R-PDT + anti-PD-1 monoclonal antibody (αPD-1) in a highly aggressive, subcutaneous AE17-OVA mesothelioma dual tumor-bearing C57BL/6 mice. We found a 46.64-fold and 61.33-fold increase in interleukin-6 (IL-6) after R-PDT and combination R-PDT + αPD-1 relative to PBS respectively, suggesting broad innate immune activation. There was a greater propensity for antigen presentation in the spleen and distal, non-irradiated tumor draining lymph nodes, as dendritic cells and macrophages had increased expression of MHC class II, CD80, and CD86, after R-PDT and combination R-PDT + αPD-1. Concurrently, there was a shift in the proportions of CD4+ T cell subsets in the spleen, and an increase in the frequency of CD8+ T cells in the distal, non-irradiated tumor draining lymph nodes. While R-PDT had an acceptable safety profile, combination R-PDT + αPD-1 induced 1.26-fold higher serum potassium and 1.33-fold phosphorus, suggestive of mild laboratory tumor lysis syndrome. Histology revealed an absence of gross inflammation in critical organs after R-PDT and combination R-PDT + αPD-1 relative to PBS-treated mice. Taken together, our findings shed light on how the abscopal effect can be induced by PDT and strengthened by combination R-PDT + αPD-1, and suggests minimal toxicities after R-PDT.Jan. 2023, Biomaterials, 292, 121918 - 121918, English, International magazine[Refereed]Scientific journal
- OBJECTIVES: We investigated the influence of the preoperative haemoglobin A1c (HbA1c) value on the prognosis and pathology of patients with lung adenocarcinoma who underwent surgery. METHODS: We reviewed the medical records of 400 lung adenocarcinoma patients who underwent lobectomy with mediastinal lymph node dissection between 2009 and 2013 using a prospectively maintained database. We stratified 400 patients into 4 groups according to the preoperative HbA1c value as follows: HbA1c ≤ 5.9 (n = 296), 6.0 ≤ HbA1c ≤ 6.9 (n = 70), 7.0 ≤ HbA1c ≤ 7.9 (n = 21) and HbA1c ≥ 8.0 (n = 12). We compared the recurrence-free survival and overall survival (OS) among these 4 groups. Univariate and multivariate analyses were performed to identify the risk factors for recurrence. RESULTS: The median follow-up period was 61.2 months. On comparing the recurrence-free survival and OS rates among these 4 groups, we found that these rates among patients in the HbA1c ≥ 8.0 group were significantly poorer compared with the other 3 groups (5-year recurrence-free survival: HbA1c ≤ 5.9, 70.4%; 6.0 ≤ HbA1c ≤ 6.9, 69.7%; 7.0 ≤ HbA1c ≤ 7.9, 70.7%; ≥8.0 HbA1c, 18.8%; P = 0.002; and 5-year OS: HbA1c ≤ 5.9, 88.7%; 6.0 ≤ HbA1c ≤ 6.9, 80.6%; 7.0 ≤ HbA1c ≤ 7.9, 90.2%; ≥8.0 HbA1c, 66.7%; P = 0.046). Patients in the HbA1c ≥ 8.0 group had significantly more tumours with vascular invasion (P = 0.041) and experienced distant metastasis significantly more often (P = 0.028) than those with other values. A multivariate analysis revealed that preoperative HbA1c ≥ 8.0 [hazard ratio (HR) 2.33; P = 0.026] and lymph node metastasis (HR 3.94; P < 0.001) were significant independent prognostic factors for recurrence. CONCLUSIONS: Our results revealed that preoperative HbA1c ≥ 8.0 is associated to poor prognosis due to the occurrence of distant metastasis and we should carefully follow these patients after surgery. CLINICAL REGISTRATION NUMBER: Hyogo Cancer Center, G-57.Lead, Oct. 2021, Interactive cardiovascular and thoracic surgery, 33(4) (4), 534 - 540, English, International magazine[Refereed]Scientific journal
- OBJECTIVES: Pleural invasion (pl) is strongly associated with the pleural lavage cytology (PLC) status. We analysed tumours with pl and evaluated the relationship between the PLC status and pl. METHODS: We retrospectively reviewed 428 surgically treated patients who had been diagnosed with non-small-cell lung cancer with pl and had their PLC status examined between 2000 and 2016. We investigated the influence of a PLC-positive status on the prognosis and searched for the factors predictive of a PLC-positive status. RESULTS: Seventy-eight (18%) patients were PLC positive. The recurrence-free survival of PLC-positive patients was significantly worse than that of PLC-negative patients in pl1 and pl2, but not in pl3 (5-year recurrence-free survival rate, PLC positive versus PLC negative: pl1, 22.0% vs 60.0%, P = 0.002; pl2, 30.4% vs 59.7%, P = 0.015; pl3, 50.0% vs 59.6%, P = 0.427). A multivariable analysis showed that the degree of pl (pl2-3 versus pl1) [odds ratio (OR) 5.34, P < 0.001] was an independent predictive factor for PLC positivity. Epidermal growth factor receptor (EGFR) mutation positivity (OR 5.48, P = 0.042) and carcinoembryonic antigen (CEA) ≥5 ng/ml (OR 3.78, P = 0.042) were associated with a PLC-positive status in patients with pl2-3. We found that the PLC-positive rate in patients with pl2-3 was 35.6%; however, if the tumour was EGFR mutation positive and had CEA ≥5 ng/ml, the PLC-positive rate increased to 77%. CONCLUSIONS: If a tumour was suspected of being pl2-3 and had EGFR mutation positivity and CEA ≥5 ng/ml, the PLC-positive rate was extremely high. CLINICAL TRIAL REGISTRATION NUMBER: Hyogo Cancer Center, G-138.Corresponding, Apr. 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 59(4) (4), 791 - 798, English, International magazine[Refereed]Scientific journal
- 医歯薬出版(株), Feb. 2021, 医学のあゆみ, 276(6) (6), 622 - 626, Japanese
- Invasion has a significant role in cancer progression, including expansion to surrounding tissue and metastasis. Previously, we assessed the invasive ability of cancer cells using an easy-to-prepare double-layered collagen gel hemisphere (DL-CGH) method by which cancer cell invasion can be easily visualized. The present study examined multiple lung adenocarcinoma and malignant pleural mesothelioma (MPM) cell lines using the DL-CGH method and identified inherently invasive cell lines. Next, by comparing gene expression between invasive and non-invasive cells by cDNA microarray, the potential candidate gene brain-expressed x-linked protein 1 (Bex1) was identified to be involved in cancer invasion, as it was highly expressed in the invasive cell lines. Downregulation of Bex1 suppressed the invasion and proliferation of the invasive tumor cell lines. The findings of the present study suggested that Bex1 may promote metastasis in vivo and could be a potential oncogene and molecular therapeutic target in lung adenocarcinoma and MPM.Dec. 2020, Oncology letters, 20(6) (6), 362 - 362, English, International magazine[Refereed]Scientific journal
- BACKGROUND: The mammalian Notch family ligands delta-like 3 (DLL3) is reported to be a potential therapeutic target for large cell neuroendocrine carcinomas (LCNEC). The effect of DLL3 expression on LCNEC prognosis has not yet been elucidated. METHODS: We reviewed the medical records of 70 LCNEC patients undergoing surgical resection between 2001 and 2015 using a prospectively maintained database. We performed immunohistochemistry for DLL3 and investigated the correlation between the sensitivity of LCNEC to platinum-based adjuvant chemotherapy. RESULTS: DLL3 expression was positive in 26 (37.1%) LCNEC patients. A total of 23 patients (32.9%) received platinum-based adjuvant chemotherapy. Among patients with DLL3 expression-positive tumors, no difference was found in the five-year overall survival (OS) or recurrence-free survival (RFS) between patients with and without adjuvant chemotherapy (surgery + chemotherapy vs. surgery alone, five-year OS: 58.3% vs. 35.7% P = 0.36, five-year RFS: 41.7% vs. 35.7% P = 0.74). In contrast, among patients with DLL3-negative tumors, significantly greater five-year OS and RFS rates were observed for patients with adjuvant chemotherapy than for those without it (surgery + chemotherapy vs. surgery alone: five-year OS: 90.0% vs. 26.9% P<0.01, five-year RFS: 80.0% vs. 21.7% P < 0.01). A multivariate analysis for the RFS revealed that adjuvant chemotherapy was a significant independent prognostic factor among patients with DLL3-negative tumors (hazard ratio [HR]: 0.05, 95% confidence interval [CI]: 0.01-0.41, P < 0.01), although it was not a factor among patients with DLL3-positive tumors (HR: 0.73, 95% CI: 0.23-2.27, P = 0.58). CONCLUSIONS: Our results revealed that DLL3 is a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: DLL3 was a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC. Among patients with DLL3 expression-negative LCNEC, platinum-based adjuvant chemotherapy significantly improved the OS and RFS, although it did not do so among patients with DLL3 expression-positive LCNEC. WHAT THIS STUDY ADDS: Our results suggest that DLL3 expression-positive LCNEC may be better treated with other types of adjuvant chemotherapy, such as the anti-DLL3 therapies if these effects are confirmed by ongoing clinical research.Lead, Sep. 2020, Thoracic cancer, 11(9) (9), 2561 - 2569, English, International magazine[Refereed]Scientific journal
- OBJECTIVES: Segmentectomies such as S1 + 2, S1 + 2+3 and S4 + 5 segmentectomy are used to treat patients with non-small-cell lung cancer (NSCLC) in the left upper lobe. However, the preservable lung volume and changes after such segmentectomies remain unknown. We compared the residual pulmonary function after thoracoscopic segmentectomy or lobectomy in the left upper lobe and examined the efficacy of S1 + 2 segmentectomy regarding postoperative pulmonary function. METHODS: Patients with left upper lobe NSCLC who underwent thoracoscopic segmentectomy or lobectomy were included. Spirometry and computed tomography were performed before and 6 months after resection, and the ipsilateral preserved lobe volume was calculated using 3-dimensional computer tomography. The percentage of postoperative/preoperative forced expiratory volume in 1 s and actual/predicted regional forced expiratory volume in 1 s (preservation rate) in the residual lobe were compared. RESULTS: Eighty-eight patients underwent lobectomy and 70 patients underwent segmentectomy (23 S1 + 2, 35 S1 + 2+3 and 12 S4 + 5 segmentectomies). The percentage of postoperative/preoperative forced expiratory volume in 1 s was 97 in S1 + 2, 82 in S1 + 2+3, 86 in S4 + 5 segmentectomy and 73 in left upper lobectomy, indicating that segmentectomy could be a meaningful approach to preserve pulmonary function. The preservation rate was 83% in S1 + 2 and 62% in S1 + 2+3 segmentectomy and was significantly higher in S1 + 2 than in S1 + 2+3 segmentectomy (P < 0.001). CONCLUSIONS: Postoperative pulmonary function and the preservable lung volume of the residual lobe after thoracoscopic S1 + 2 segmentectomy were well-preserved among other segmentectomies and lobectomy. Thoracoscopic S1 + 2 segmentectomy is a good alternative for preserving postoperative function.Sep. 2020, Interactive cardiovascular and thoracic surgery, 31(3) (3), 331 - 338, English, International magazine[Refereed]Scientific journal
- BACKGROUNDS AND OBJECTIVES: Recent studies have suggested that insulinoma-associated protein 1 (INSM1) is a useful marker for pathological diagnosis of pulmonary neuroendocrine tumors. In the present study, we investigated the association between INSM1 expression and prognosis in patients with pulmonary high-grade neuroendocrine carcinomas (HGNEC) and assessed the usefulness of INSM1 as a prognostic biomarker in these patients. METHODS: Seventy-five consecutive patients with HGNEC who underwent complete surgical resections from January 2000 to December 2018 were enrolled in this study. We classified these patients into two groups: the INSM1-positive group (n = 59) and INSM1-negative group (n = 16). We compared the clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS) between the groups. In addition, we performed univariate and multivariate analyses to identify the prognostic factors associated with postoperative survival. RESULTS: Significant differences in tumor diameter and vascular invasion between the groups were found. OS and RFS were significantly poorer in the INSM1-positive group than in the INSM1-negative group. Univariate and multivariate analyses revealed that INSM1 expression was the strongest predictor of poor prognosis for OS and RFS. CONCLUSIONS: INSM1 expression had the greatest influence on the prognosis in patients with HGNEC and may be a prognostic biomarker in these patients.Aug. 2020, Journal of surgical oncology, 122(2) (2), 243 - 253, English, International magazine[Refereed]Scientific journal
- Mediastinal leiomyosarcoma is an aggressive tumor that primarily occurs in the posterior mediastinum. A bronchogenic cyst is a benign lesion that often develops in the mediastinum close to the thoracic trachea and has been reported to be the origin of certain malignancies. The present study reports an extremely rare case of an anterior mediastinal leiomyosarcoma that was considered to have originated from a bronchogenic cyst. An 82-year-old woman complained of chest pain, presenting an abnormal 70 mm mass shadow in the anterior mediastinum of a chest CT scan. Mediastinal tumor resection was performed and the tumor was diagnosed as a leiomyosarcoma. As the tumor was located adjacent to a bronchogenic cyst, it was considered to have originated from the remnant tissue of the cyst. Recurrent lesions were noted in the right lower lobe on CT scan 24 months after surgery.Mar. 2020, Molecular and clinical oncology, 12(3) (3), 244 - 246, English, International magazine[Refereed]Scientific journal
- A pneumatocele is a cystic change of the lung that is caused by a check valve in the bronchiole due to infection, trauma and positive-pressure ventilation. We herein report a case of pneumatocele triggered by using of continuous positive airway pressure (CPAP) for sleep apnea syndrome (SAS) after pulmonary resection. A 69-year-old man underwent right upper lobectomy for lung cancer and developed interstitial pneumonia (IP) 10th postoperative day (POD). He was treated with steroid pulse therapy (solmedrol 500 mg × 3 days), and thereafter with oral steroid therapy (predonin 30mg/day). Well responded to the steroid therapy, IP was improved. However, he noticed bloody sputum 29th POD, and chest computed tomography showed a giant cystic lesion on the dorsal right lower lobe. We resected the cyst and the pathological findings revealed that the cystic lesion was pneumatocele, and CPAP was strongly suspected of triggering this disease.2020, Respiratory medicine case reports, 30, 101119 - 101119, English, International magazine[Refereed]Scientific journal
- Rhabdomyosarcoma is a well-known neoplasm in children that frequently occurs in the extremities, the head and neck region, and the genitourinary tract. To the best of our knowledge, pulmonary primary rhabdomyosarcoma in adults is exceedingly rare, and few resected cases have been reported. We report a case of pulmonary primary rhabdomyosarcoma that was surgically resected then treated with adjuvant chemotherapy (vincristine, actinomycin-D and cyclophosphamide). At 9 months after surgery, the patient is free from disease. Although the prognosis of rhabdomyosarcoma is unfavorable, surgical resection and adjuvant therapy could be a potential treatment strategy for pulmonary primary rhabdomyosarcoma.Dec. 2019, General thoracic and cardiovascular surgery, 67(12) (12), 1089 - 1092, English, Domestic magazine[Refereed]Scientific journal
- [Mediastinal Shift Due to the Rapidly Expanded Giant Bulla Probably Caused by the Lung Cancer].A 39-year-old man was admitted to our hospital with back pain and numbness of the left leg. Computed tomography (CT) showed a giant bulla and tumor in the right lung, mediastinal shift to the left side and lesions suggestive of metastatic sacral tumor. Three days later, the patient visited the emergency room with dyspnea and tachycardia. Chest CT showed the progression of mediastinal shift due to the rapid expansion of the giant bulla, and an emergency surgery was performed. After induction of anesthesia, sudden respiratory and circulatory failure occurred. Considering further expansion of the giant bulla by positive pressure ventilation, veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO) was applied. After establishing ECMO, the condition of the patient became stable and the giant bulla could be resected successfully.Dec. 2019, Kyobu geka. The Japanese journal of thoracic surgery, 72(13) (13), 1068 - 1071, Japanese, Domestic magazine[Refereed]Scientific journal
- [Left Paraganglioma in the Posterior Mediastinum].A 69-year-old man with hypertension was referred for an abnormal shadow detected on chest computed tomography(CT) at a medical checkup. Enhanced CT showed a highly enhanced posterior mediastinal tumor of 34×27 mm. Magnetic resonance imaging (MRI) revealed a low signal intensity on T1-weighted images and high signal intensity on T2-weighted images. Thus, a neurogenic tumor was suspected and the surgery was performed. The tumor was carefully dissected as it was hyper-vascular and hemorrhagic. Immediately after tumor resection, the patient's blood pressure rapidly decreased, and phenylephrine hydrochloride was needed to maintain the blood pressure. The pathological diagnosis was paraganglioma.Dec. 2019, Kyobu geka. The Japanese journal of thoracic surgery, 72(13) (13), 1072 - 1075, Japanese, Domestic magazine[Refereed]Scientific journal
- BACKGROUND: Segmentectomy has shown a beneficial effect on preserving lung function after resection. However, the preservable lung volume and changes after thoracoscopic segmentectomy remain unknown. We compared the residual lung function after thoracoscopic segmentectomy and lobectomy, using a novel three-dimensional computed tomography-based volumetric method. METHODS: Seventy-four patients who received thoracoscopic segmentectomy were matched to the 74 patients who received thoracoscopic lobectomy. Spirometry and computed tomography were performed before and 6 months after resection, and the ipsilateral residual preserved and nonoperated lobe volume and the contralateral lung volume were calculated using three-dimensional computed tomography. The percentage of actual/predicted regional forced expiratory volume in 1 second (the preservation rate) in each lobe (measured by volumetry and spirometry) was compared with the extent of resection and procedural difficulty (typical or atypical segmentectomy). RESULTS: The postoperative lung function was significantly more well preserved in segmentectomy than in lobectomy. After segmentectomy and lobectomy, the regional forced expiratory volume in 1 second of the ipsilateral unaffected lobe was increased in comparison with the preoperative value, whereas that of the residual lobe rescued by segmentectomy was decreased. The preservation rates of the residual and unaffected lobes were inversely and positively correlated, respectively, with the extent of the resected segment. The preservation rates of the residual lobe after typical or atypical segmentectomy were not significantly different. CONCLUSIONS: Although the decrease in the actual lung function of the residual lobe was greater than predicted and increased with increasing extent of resection, segmentectomy preserved the whole lung function better than lobectomy.Nov. 2019, The Annals of thoracic surgery, 108(5) (5), 1543 - 1550, English, International magazine[Refereed]Scientific journal
- BACKGROUND: The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). METHODS: From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small-sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small-sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small-sized SCLC (sSCLC). RESULTS: A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small-sized triple-positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small-sized nontriple-positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence-free survival (RFS) and tumor-specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. CONCLUSIONS: The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.Nov. 2019, Thoracic cancer, 10(11) (11), 2152 - 2160, English, International magazine[Refereed]Scientific journal
- [Tumor-induced Hypophosphatemic Osteomalacia Caused by a Chest Wall Tumor].Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disease characterized by hypophosphatemia and skeletal undermineralization. Overproduction of fibroblast growth factor 23( FGF23) from the responsible tumor is reported to be a causative factor. Removing the tumor is the only effective treatment for TIO, but identifying the tumor is sometimes difficult. A 43-year-old man complained of heel pain 4 years earlier, and the pain gradually expanded to the whole body. As a blood test showed the elevation of the serum FGF23 level and hypophosphatemia, he was diagnosed with FGF23-related hypophosphatemia. Chest computed tomography (CT) showed a 10-mm nodule in the right chest wall. Venous sampling for FGF23 revealed considerable elevation of the FGF23 level in the right subclavian vein. Therefore, a chest wall tumor was suspected as the tumor responsible for TIO, and surgical resection was performed. After surgery, hypophosphatemia improved within several days, and the FGF23 level also normalized.Aug. 2019, Kyobu geka. The Japanese journal of thoracic surgery, 72(8) (8), 570 - 573, Japanese, Domestic magazine[Refereed]Scientific journal
- BACKGROUND: Large-cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) are categorized as high-grade neuroendocrine carcinoma (HGNEC). We analyzed the efficacy of perioperative chemotherapy for HGNEC and the prognostic factors. METHODS: We retrospectively reviewed the medical records of patients who underwent tumor resection and were diagnosed with HGNEC between January 2001 and December 2014. The overall survival (OS) was estimated by the Kaplan-Meier method. Propensity score matching was performed to compare the OS between the treatment groups. Multivariate analyses using a Cox proportional hazards model were performed to search for prognostic factors for HGNEC. RESULTS: We analyzed 146 HGNEC patients (LCNEC n=92, SCLC n=54) without synchronous multiple cancers, who underwent complete resection. Seventy patients (LCNEC n=31, SCLC n=32) received perioperative chemotherapy and all of them received a platinum-based anticancer drug. Perioperative chemotherapy significantly improved the 5-year OS rates of HGNEC patients (all stages: 74.5% vs. 34.7%, P<0.01, stage I: 88.5% vs. 40.0%, P<0.01). The efficacy of perioperative chemotherapy was similar between LCNEC and SCLC patients [LCNEC all stages: hazard ratio (HR) 0.27, P<0.01, LCNEC stage I: HR 0.27, P=0.01; SCLC all stages: HR 0.38, P=0.02, SCLC stage I: HR 0.34, P=0.06]. The survival benefit of perioperative chemotherapy for HGNEC patients was confirmed by propensity score matching analysis (HR 0.31, P<0.01). The multivariate analysis revealed that perioperative chemotherapy (HR 0.29, P<0.01), sublobar resection (HR 2.11, P=0.04), and lymph node metastasis (HR 3.34, P<0.01) were independently associated with survival. CONCLUSIONS: Surgical resection combined with perioperative chemotherapy was considered to be effective even for stage I HGNEC patients. Sublobar resection might increase the risk of death in HGNEC patients.Lead, Apr. 2019, Journal of thoracic disease, 11(4) (4), 1145 - 1154, English, International magazine[Refereed]Scientific journal
- ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)-rearranged lung cancer is rare and comprises only 1% of lung adenocarcinoma cases. It has recently been reported to have good response to crizotinib, a tyrosine kinase inhibitor of anaplastic lymphoma kinase. Driver oncogene mutations with approved therapies seldom coexist with a high expression of Programmed death-ligand 1 (PD-L1). The present case report describes a rare case of ROS1 rearrangement with high-PD-L1-expressing occult lung adenocarcinoma. A 32-year-old woman presented with chest pain and a prolonged cough. Chest computed tomography (CT) revealed a 57×36-mm tumor in the mediastinum, with no tumors detected in other regions. Positron emission tomography (PET)-CT showed a strong fluorodeoxyglucose accumulation in the tumor (SUVmax 13.2). Mediastinal tumor resection was completely resected using a video-assisted thoracic surgery approach. Pathological examination showed the tumor cells were positive for thyroid transcription factor 1, Napsin-A, ROS1, and PD-L1 (tumor proportion score >99%). ROS1 rearrangement was confirmed by fluorescence in situ hybridization. The mediastinal tumor was diagnosed as mediastinal lymph node metastasis of ROS1-rearranged PD-L1 high-expression undifferentiated lung adenocarcinoma (pathological stage 3, TxN2M0). Two months after the operation, the CT scan showed multiple mediastinum lymph nodes metastases with rapid tumor growth. The patient achieved a complete response after three cycles of S-1 plus cisplatin with concurrent radiotherapy 60 Gy/30 Fr.Lead, Jan. 2019, Oncology letters, 17(1) (1), 488 - 491, English, International magazine[Refereed]Scientific journal
- Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor prognosis and closely related to exposure to asbestos. MPM is a heterogeneous tumor with three main histological subtypes, epithelioid, sarcomatoid, and biphasic types, among which sarcomatoid type shows the poorest prognosis. The Ror-family of receptor tyrosine kinases, Ror1 and Ror2, is expressed in various types of tumor cells at higher levels and affects their aggressiveness. However, it is currently unknown whether they are expressed in and involved in aggressiveness of MPM. Here, we show that Ror1 and Ror2 are expressed in clinical specimens and cell lines of MPM with different histological features. Studies using MPM cell lines indicate that expression of Ror2 is associated tightly with high invasiveness of MPM cells, whereas Ror1 can contribute to their invasion in the absence of Ror2. However, both Ror1 and Ror2 promote proliferation of MPM cells. We also show that promoted invasion and proliferation of MPM cells by Ror signaling can be mediated by the Rho-family of small GTPases, Rac1, and Cdc42. These findings elucidate the critical role of Ror signaling in promoting invasion and proliferation of MPM cells.Jul. 2018, Genes to cells : devoted to molecular & cellular mechanisms, 23(7) (7), 606 - 613, English, International magazine[Refereed]Scientific journal
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), RO7 - 2, JapaneseIL-6 signalの阻害は、肺癌幹細胞を標的にした新規治療法になりうるか
- (一社)日本呼吸器外科学会, Nov. 2017, 日本呼吸器外科学会雑誌, 31(7) (7), 885 - 889, Japanese[Refereed]
- In the present study, we successfully generated lung cancer stem cell (CSC)-like cells by introducing a small set of transcription factors into a lung cancer cell line. In addition to properties that are conventionally referred to as CSC properties, the lung induced CSCs exhibited the ability to form lung cancer-like tissues in vitro with vascular cells and mesenchymal stem cells, which showed structures and immunohistological patterns that were similar to human lung cancer tissues. We named them "lung cancer organoids". We found that interleukin-6 (IL-6), which was expressed in the lung induced CSCs, facilitates the formation of lung cancer organoids via the conversion of mesenchymal stem cells into alpha-smooth muscle actin (αSMA)-positive cells. Interestingly, the combination of anti-IL-6 antibody and cisplatin could destroy the lung cancer organoids, while cisplatin alone could not. Furthermore, IL-6 mRNA-positive cancer cells were found in clinical lung cancer samples. These results suggest that IL-6 could be a novel therapeutic target in lung cancer.Lead, Sep. 2017, Scientific reports, 7(1) (1), 12317 - 12317, English, International magazine[Refereed]Scientific journal
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 416 - 416, Japanese
- OBJECTIVE: Radical resection for thoracic malignancies that invade the great vessels or heart structure is an uncommon, high-risk operation. To help surgeons determine therapeutic strategy, we reviewed the patient characteristics and outcomes of combined thoracic and cardiovascular surgery for thoracic malignancies. METHODS: Surgical resections of lung cancer, mediastinal tumor and pulmonary artery sarcoma invading great vessels or heart structures were reviewed from the literature. RESULTS: Pneumonectomy was often performed for lung cancer invading the aorta, superior vena cava, and left atrium. Complete resection (R0), no mediastinal lymph node metastasis and without using cardiopulmonary bypass led to a good prognosis. Induction therapy was often performed for complete resection. Regarding mediastinal tumors, thymic epithelial tumors or germ cell tumors occasionally invaded the great vessels or heart structures. For these malignancies, multimodality therapy was often performed, and complete resection could be one of the prognostic factors. The resection of primary pulmonary artery sarcoma (PPAS) is also a combined thoracic and cardiovascular surgery. The primary treatment for PPAS is surgical resection; specifically, pulmonary endarterectomy and pneumonectomy, because PPAS has substantial resistance to chemotherapy or radiotherapy. The prognosis of PPAS is poor, but surgical resection has potential for long-term survival. CONCLUSION: Although these surgeries are uncommon and invasive for the patients, selecting appropriate patients, aggressive multimodality therapy, and performing combined thoracic and cardiovascular surgery can contribute to a good outcome.Jul. 2017, General thoracic and cardiovascular surgery, 65(7) (7), 365 - 373, English, Domestic magazine[Refereed]Scientific journal
- Jul. 2017, The Annals of thoracic surgery, 104(1) (1), 370 - 370, English, International magazine[Refereed]
- (NPO)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), O10 - 2, Japanese続発性気胸に対する手術症例の検討Research society
- (NPO)日本肺癌学会, Feb. 2017, 肺癌, 57(1) (1), 41 - 45, Japanese[Refereed]
- Psf3 is a prognostic biomarker in lung adenocarcinoma: a larger trial using tissue microarrays of 864 consecutive resections.OBJECTIVES: Partner of Sld five (Psf) 3 is a member of the evolutionarily conserved heterotetrameric complex GINS (Go-Ichi-Ni-San). We previously reported that Psf3 could serve as a biomarker of poor prognosis in lung adenocarcinoma. Here, we used tissue microarrays to analyse Psf3 expression in lung adenocarcinoma and investigated whether its expression is associated with survival outcomes. METHODS: The study included 864 consecutive patients with lung adenocarcinoma who underwent complete resection at Hyogo Cancer Center between January 2002 and December 2009. Tissue microarrays were prepared, and Psf3 was detected using mouse antihuman Psf3 primary monoclonal antibodies. The status of Psf3 expression was determined using these microarrays. RESULTS: Of the 864 patients, 375 had high-positive Psf3 expression and 489 had low-positive expression. Psf3 expression was significantly associated with age, sex, T factor, lymph node metastasis, stage and P factor. The 5-year disease-free survival (DFS) rate was significantly lower in patients with high-positive Psf3 expression than in those with low-positive expression, and Psf3 expression, sex, age, T factor and lymph node metastasis were identified as independent and significant prognostic determinants. Among patients with Stage I adenocarcinoma, the 5-year DFS rate was significantly lower in those with high-positive Psf3 expression than in those with low-positive expression, and Psf3 expression was the most powerful survival predictor. CONCLUSIONS: The present findings strengthened our previous data demonstrating that high Psf3 expression in primary lung adenocarcinoma plays an important role in disease progression and is a prognostic indicator, particularly in early-stage adenocarcinoma.Oct. 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 50(4) (4), 758 - 764, English, International magazine[Refereed]Scientific journal
- Disturbance of the surgical view during video-assisted thoracic surgery (VATS) as a result of blood oozing from the wound surface of the access port may lead to additional stress on surgeons and is difficult to prevent. We used a wound edge protector with oxidized regenerated cellulose (ORC) rings for the wound surfaces of the access ports and eliminated the problem. Furthermore, no hemostatic procedure was required for the wound surface before wound closure because the ORC rings completely stopped wound surface bleeding during the operation. ORC rings enhanced protection of the thoracoscopic port and the quality of VATS.Feb. 2016, The Annals of thoracic surgery, 101(2) (2), 786 - 8, English, International magazine[Refereed]Scientific journal
- The GINS complex associates with cell division cycle (Cdc) protein 45 and mini-chromosome maintenance (Mcm) proteins 2-7 to form the Cdc45-Mcm-GINS (CMG) complex, which is essential for DNA duplication. One member of the GINS complex is Psf3. We previously found that increased Psf3 expression was strongly associated with poor survival in lung adenocarcinoma. Here, we investigated the role of Psf3 expression in non-small-cell lung cancer (NSCLC). We verified Psf3 expression in human NSCLC tissues (180 patients) and cell lines. Immunohistochemical analysis revealed that the overexpression of Psf3 was significantly associated with vessel invasion (P = 0.016), lymphatic invasion (P = 0.002), and pleural invasion (P = 0.036). The overall survival rate in patients with Psf3 overexpression was significantly lower than that in patients without Psf3 overexpression (P = 0.006). Multivariate survival analysis revealed Psf3 expression to be an independent risk factor for an unfavorable outcome (P = 0.049). A proximal ligation assay showed interactions between Psf3 and other CMG components (such as Mcm2 and Cdc45) in both NSCLC specimens and cell lines, indicating that Psf3 acted as the CMG complex, which could lead to excessive proliferation. Knockdown of Psf3 inhibited the proliferation of both cell lines by delaying the S phase, which revealed that Psf3 played an important role in cancer proliferation. Thus, Psf3 acted as the CMG complex, promoting excessive proliferation. These results suggest that Psf3 inhibition might be a therapeutic target for NSCLC with Psf3 overexpression.Nov. 2015, Cancer science, 106(11) (11), 1625 - 34, English, International magazine[Refereed]Scientific journal
- AIM: We examined the advantages of thoracoscopy over thoracotomy in terms of perioperative outcomes and toleration of adjuvant chemotherapy. METHODS: Between April 2010 and March 2013, 657 patients with non-small-cell lung cancer who underwent lobectomy were classified into thoracoscopy (308 patients) and thoracotomy (349 patients) groups and compared. RESULTS: The thoracoscopy group had less blood loss compared to the thoracotomy group (p < 0.001). When limiting the analysis to pathological stage I patients, the results were similar (p < 0.001). In addition, the difference in blood loss between the 2 groups was greater in patients with severe pleural adhesions. The postoperative morbidity of the thoracoscopy group was significantly less than that of the thoracotomy group (13.3% vs. 21.2%, p < 0.001), and this result was similar when analyzing the pathological stage I patients (12.6% vs. 20.6%, p = 0.001). A higher percentage of the thoracoscopy group received both the full planned course and dose of adjuvant chemotherapy compared to the thoracotomy group (84.2% vs. 65.8%, p = 0.032). CONCLUSIONS: These results indicate that totally thoracoscopic lobectomy is the more beneficial surgical approach with regard to the incidence of postoperative complications and toleration of adjuvant chemotherapy.Oct. 2015, Asian cardiovascular & thoracic annals, 23(8) (8), 950 - 7, English, International magazine[Refereed]Scientific journal
- Ruptured thymoma causing a hemothorax: A case report.A thymoma is a neoplasm that arises from the epithelial cells of the thymus, and may cause various signs and symptoms dependent upon its local extent. A non-traumatic hemothorax is extremely rare. The present study reports the case of a 77-year-old female who presented with an acute onset of chest pain. Imaging procedures revealed a mass occupying the anterior mediastinum and left hemithorax, and a left pleural effusion. Progressive anemia was noted following admission. Left hemothorax due to rupture of the anterior mediastinal mass was suspected, and emergency surgery was performed. Hemorrhage was observed on the cut surface of the tumor. An analysis of frozen sections indicated a thymoma, and a thymo-partial thymectomy was subsequently performed to remove as much of the hematoma as possible. The patient was discharged on post-operative day 13 following an uneventful recovery. The present case suggests that in previously healthy individuals, sudden-onset dyspnea and chest pain co-occurring with an acute widening of the mediastinum observed on roentgenograph may be indicative of a ruptured thymoma.Sep. 2015, Oncology letters, 10(3) (3), 1810 - 1812, English, International magazine[Refereed]Scientific journal
- (一社)神緑会, Aug. 2015, 神緑会学術誌, 31, 57 - 59, Japanese[Refereed]
- OBJECTIVES: We evaluated the clinical benefit of segmentectomy for patients with cT1bN0M0 lung cancer. METHODS: We retrospectively reviewed the medical records of 178 patients who underwent lobectomy or segmentectomy for cT1bN0M0 lung adenocarcinoma and squamous cell carcinoma from January 1995 to December 2005. We investigated the association of surgical outcomes with the presence of pathological invasion. RESULTS: The median follow-up period was 93.4 months. Of 178 patients, 37 were scheduled for segmentectomy, but 6 of these patients were switched to receive lobectomy due to surgical N1 or N2 in 3 patients and insufficient surgical margins in 3 patients. In total, 31 patients underwent segmentectomy, and 147 underwent lobectomy. The 5-year overall survival (OS) was similar between the patients who underwent lobectomy (5-year OS, 81.6%) and segmentectomy (5-year OS, 77.4%, P = 0.73). Among pN0 patients without pathological invasion, there was no difference in OS between patients who underwent lobectomy (5-year OS, 89.9%) and segmentectomy (5-year OS, 88.9%, P = 0.80). In contrast, among pN0 patients with pathological invasion, OS was greater in patients who underwent lobectomy (5-year OS, 80.9%) than in those who underwent segmentectomy (5-year OS, 54.6%; P = 0.19). Moreover, a significantly higher rate of local and local + distant recurrence was observed in patients who underwent segmentectomy (45%) than in those who underwent lobectomy (15%) in this group (P = 0.02). CONCLUSIONS: The results of our study suggest that segmentectomy may not be recommended for cT1b tumours if pathological invasion is suspected before surgery.Lead, Jul. 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 48(1) (1), 77 - 82, English, International magazine[Refereed]Scientific journal
- OBJECTIVES: Positive pleural lavage cytology (PLC) findings are considered to be predictive of a poor prognosis in patients with non-small-cell lung cancer (NSCLC). We investigated the clinical benefit of adjuvant chemotherapy for lung adenocarcinoma patients with positive PLC findings. METHODS: We retrospectively reviewed the medical records of lung adenocarcinoma patients who underwent tumour resection and had positive PLC findings between January 2000 and December 2009. RESULTS: Fifty-three patients (4.8%) of 1114 patients with lung adenocarcinoma had positive PLC findings. The median follow-up period was 33.6 months. Adjuvant chemotherapy was administered to 24 patients (adjuvant chemotherapy group); 7, 8 and 9 patients had pathological Stage I, II and III, respectively . The surgery-alone group comprised 29 patients; 12, 8 and 9 patients had pathological Stage I, II and III, respectively. The 5-year recurrence-free survival (RFS) rates were 34.6 and 15.7% (P < 0.01) in adjuvant chemotherapy and surgery-alone groups, respectively. The rate of distant recurrence was significantly reduced in the adjuvant chemotherapy group (25.0 and 58.6%; P = 0.01). Even for Stage I cases, adjuvant chemotherapy tended to improve the 5-year RFS rate compared with surgery alone (60.1 and 29%; P = 0.11). Multivariate analysis for RFS revealed that adjuvant chemotherapy [hazard ratio (HR), 0.45; P = 0.03], tumour size >30 mm (HR, 2.23; P = 0.02) and lymph node metastasis (HR, 2.67; P < 0.01) were significant independent prognostic factors for recurrence. CONCLUSIONS: Adjuvant chemotherapy for lung adenocarcinoma patients with positive PLC findings significantly improved recurrence-free survival.Lead, Jul. 2015, Interactive cardiovascular and thoracic surgery, 21(1) (1), 34 - 9, English, International magazine[Refereed]Scientific journal
- [Perforation of the Mediastinal Mature Teratoma;Report of a Case].The mediastinal mature teratoma is uncommon in adult and sometimes ruptures. We present a case of perforation of mediastinal mature teratoma. A 22-year-old man, who had been scheduled for surgery to resect anterior mediastinal teratoma, was referred to our hospital due to sudden chest pain. The enhanced computed tomography findings suggested a perforation of the teratoma and the emergency surgery was performed. Extirpation of the tumor with partial resection of right upper lung, pericardium, and superior vena cava was performed. The histological diagnosis was mature teratoma and the defect of the mediastinal pleura was found to be the site of perforation. The patient was well and discharged from the hospital without complications.Jul. 2015, Kyobu geka. The Japanese journal of thoracic surgery, 68(7) (7), 546 - 9, Japanese, Domestic magazine[Refereed]Scientific journal
- Pleural lavage cytology as an independent prognostic factor in non-small-cell lung cancer patients with stage I disease and adenocarcinoma.We previously reported that cancer cells may be detected through pleural lavage cytology (PLC). In this study, we sought to re-examine the prognostic significance of the PLC status based on an extended dataset with an additional follow-up period. Pleural lavage following thoracotomy was cytologically examined in 1,317 consecutive patients who were diagnosed with NSCLC between 1987 and 2004 at the Thoracic Surgery Units of Kobe University Graduate School of Medicine and Hyogo Cancer Center. Among the investigated patients, 46 exhibited positive cytological findings. The prognosis of these patients was significantly worse compared to that of patients without positive PLC. Of the 844 pathological stage I patients, 18 had a positive PLC status and their prognosis was significantly worse compared to that of patients with stage I disease without positive PLC. In conclusion, positive PLC findings were associated with a poor prognosis and this finding was significant for patients with stage I disease. These results suggest the need for PLC status evaluation during staging and treatment planning in patients with NSCLC.Jan. 2015, Molecular and clinical oncology, 3(1) (1), 244 - 248, English, International magazine[Refereed]Scientific journal
- Pulmonary large cell neuroendocrine carcinoma exhibiting extensive pagetoid spread in the bronchial epithelium: A case report.Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive malignant tumor, which was proposed as a novel type of neuroendocrine tumor in 1991. Although it is categorized as a non-small cell lung carcinoma, the precise pathological condition is unknown due to its rare occurrence. The present study outlines the case of a patient presenting with an LCNEC that exhibited pagetoid spread from the region of the primary tumor to the bronchial epithelium (distance, >30 mm). The pagetoid spread was unconfirmed preoperatively, however, was identified by intraoperative rapid diagnosis. This caused us to suffer the perioperative decision of additional resection and resulted in an incomplete resection, as suture of the bronchus was not possible. Pagetoid spread, which is often apparent in the breast, presents as a rare pattern of infiltration of cancer cells when a massive carcinoma is identified beneath the intraepithelial spread. Although preoperative diagnosis of pagetoid spread is difficult due to its rarity and undefined clinical features, it is important for surgeons and pathologists treating lung cancer patients to be aware of potential pagetoid spread in the thoracic region.Lead, Dec. 2014, Oncology letters, 8(6) (6), 2621 - 2623, English, International magazine[Refereed]Scientific journal
- Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer.The histological subtype of non-small-cell lung cancer (NSCLC) is a significant factor when selecting treatment strategies. However, cases are occasionally encountered that are diagnosed as 'not otherwise specified' (NOS) prior to surgery, due to an uncertain histological subtype. The present study investigated the prognostic significance of the NOS subtype for patients with resectable NSCLC. Between 2001 and 2011, 1,913 patients were diagnosed with NSCLC using transbronchial biopsy and underwent surgical resection at two facilities in Japan. Of these patients, 151 (7.9%) were pre-operatively diagnosed with NSCLC-NOS (NOS group) and the remainder had confirmed histological subtypes (confirmed group). The present study compared the clinicopathological features and prognoses of these groups. Analyses of resected specimens revealed that pleomorphic cell carcinoma, large cell neuroendocrine cell carcinoma, large cell carcinoma and adenosquamous carcinoma were significantly more common in the NOS group than in the confirmed group (P<0.001, P=0.002, P=0.019 and P=0.014, respectively). The five-year survival rate was significantly poorer in the NOS group (60.5 vs. 67.1%; P=0.010), particularly for stage I disease (70.8 vs. 80.7%; P=0.007). The results of a multivariate analysis of overall survival indicated that NOS was a significant independent prognostic factor (hazard ratio, 1.40; 95% confidence interval, 1.02-1.86; P=0.041). These results indicated that pre-operative NOS was significantly associated with poorer survival, including for stage I disease. In conjunction with other clinicopathological parameters, NOS can be a useful prognostic factor when deciding on a treatment strategy for NSCLC.Sep. 2014, Oncology letters, 8(3) (3), 1017 - 1024, English, International magazine[Refereed]Scientific journal
- (一社)日本外科学会, Mar. 2014, 日本外科学会雑誌, 115(臨増2) (臨増2), 224 - 224, Japanese
- OBJECTIVES: The purpose of this study was to compare the efficacy of 320-detector row computed tomography (CT) with that of 64-detector row CT for three-dimensional assessment of pulmonary vasculature of candidates for pulmonary segmentectomy. METHODS: We included 32 patients who underwent both 320- and 64-detector CT before pulmonary segmentectomy, which was performed by cutting the pulmonary artery and bronchi of the affected segment followed by dissection of the intersegmental plane along the intersegmental vein. Before the operation, three-dimensional pulmonary vasculature images were obtained for each patient, and the arteries and intersegmental veins of the affected segments were identified. Two thoracic surgeons independently assessed the vessels with visual scoring systems, and kappa analysis was used to determine interobserver agreement. The Wilcoxon signed-rank test was used to compare the visual scores for the assessment of the visualization capabilities of the two methods. In addition, the final determination of pulmonary vasculature at a given site was made by consensus from thoracic surgeons during operation, and receiver operating characteristic analysis was performed to compare their efficacy of pulmonary vasculature assessment. Sensitivity, specificity and accuracy of either method were also compared by means of McNemar's test. RESULTS: Of the 32 cases, there were no operative complications, but 1 patient died of postoperative idiopathic interstitial pneumonia. Visualization scores for the pulmonary vessels were significantly higher for 320- than those for 64-detector CT (P < 0.0001 for the affected arteries and P < 0.0001 for the intersegmental veins). As for pulmonary vasculature assessment, the areas under the curve showed no statistically significant differences in between the two methods, while the specificity and accuracy of intersegemental vein assessment were significantly better for 320- than those for 64-detector row CT (P < 0.05). Interobserver agreement for the assessment yielded by either method was almost perfect for all cases. CONCLUSIONS: Three hundred and twenty-detector row CT is more useful than conventional 64-detector row CT for preoperative three-dimensional assessment of pulmonary vasculature, especially when we identify the intersegmental veins, in candidates for pulmonary segmentectomy.Dec. 2013, Interactive cardiovascular and thoracic surgery, 17(6) (6), 974 - 80, English, International magazine[Refereed]Scientific journal
- (NPO)日本肺癌学会, Oct. 2013, 肺癌, 53(5) (5), 394 - 394, Japanese
- OBJECTIVE: Pulmonary large cell neuroendocrine carcinoma is a rare high-grade malignant tumor. Because large cell neuroendocrine carcinoma is rare, the optimal treatment, including perioperative chemotherapy, has not been defined. We retrospectively analyzed the correlation among the effectiveness of perioperative chemotherapy in treating large cell neuroendocrine carcinoma, pathologic stage, and immunoreactivity to neuroendocrine markers. METHODS: A total of 63 patients with pulmonary large cell neuroendocrine carcinoma undergoing surgical resection from 2001 to 2009 were included. The resected tumors were immunohistochemically stained with the 3 neuroendocrine markers synaptophysin, chromogranin A, and neural cell adhesion molecule. We categorized patients who were positive for all 3 markers as the triple-positive group and those who were negative for 1 or 2 markers as the non-triple-positive group. RESULTS: Perioperative chemotherapy resulted in better overall survival than surgery alone (P = .042). Multivariate analysis of survival revealed that perioperative chemotherapy was a significant independent prognostic factor (hazard ratio, 0.323; 95% confidence interval, 0.112-0.934; P = .0371). Among the patients who received perioperative chemotherapy, the non-triple-positive group had a significantly greater 5-year survival rate than the triple-positive group (P = .0216). Moreover, among the non-triple-positive group, a significantly greater 5-year survival rate was observed for the patients who underwent surgery with chemotherapy than for those who underwent surgery without chemotherapy (P = .0081). In contrast, no difference was found in 5-year survival between patients with chemotherapy and those without chemotherapy when the tumors were triple positive. CONCLUSIONS: Our results suggest that perioperative chemotherapy might benefit the survival of patients with pulmonary large cell neuroendocrine carcinoma, in particular when the tumors are not immunoreactive to all 3 neuroendocrine markers.Mar. 2013, The Journal of thoracic and cardiovascular surgery, 145(3) (3), 839 - 46, English, International magazine[Refereed]Scientific journal
- (NPO)日本肺癌学会, Oct. 2012, 肺癌, 52(5) (5), 659 - 659, Japanese
- (一社)日本外科学会, Mar. 2012, 日本外科学会雑誌, 113(臨増2) (臨増2), 232 - 232, Japanese
- (一社)日本呼吸器外科学会, Jan. 2012, 日本呼吸器外科学会雑誌, 26(1) (1), 11 - 16, Japanese[Refereed]
- (NPO)日本肺癌学会, Oct. 2011, 肺癌, 51(5) (5), 405 - 405, Japanese
- Lead, 克誠堂出版(株), Aug. 2011, 日本胸部臨床, 70(8) (8), 868 - 874, Japanese[Refereed]
- (一社)日本呼吸器外科学会, Jul. 2011, 日本呼吸器外科学会雑誌, 25(5) (5), 509 - 512, Japanese[Refereed]
- (一社)日本呼吸器外科学会, Apr. 2011, 日本呼吸器外科学会雑誌, 25(3) (3), O30 - 03, Japanese大細胞神経内分泌癌(LCNEC)に対する補助化学療法とchemo sensitivityに関する検討
- Lead, (一社)日本呼吸器外科学会, Mar. 2011, 日本呼吸器外科学会雑誌, 25(2) (2), 198 - 202, Japanese[Refereed]
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 348 - 348, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 355 - 355, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 361 - 361, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 460 - 460, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 529 - 529, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 544 - 544, Japanese
- (NPO)日本肺癌学会, Nov. 2025, 肺癌, 65(5) (5), 548 - 548, Japanese
- (NPO)日本肺癌学会, Oct. 2025, 肺癌, 65(6) (6), 993 - 993, Japanese
- (NPO)日本肺癌学会, Oct. 2025, 肺癌, 65(6) (6), 994 - 994, Japanese
- (一社)日本胸部外科学会, Oct. 2025, 日本胸部外科学会定期学術集会, 78回, LWS1 - 4, Japanese胸腺上皮性腫瘍におけるトランスレーショナル研究 縦隔脂肪肉腫のトランスクリプトーム解析 組織型別の分子特徴と治療標的の検討
- (一社)日本胸部外科学会, Oct. 2025, 日本胸部外科学会定期学術集会, 78回, LDB1 - 1, Japanese肺癌に対する低侵襲手術アプローチ 周術期比較 多孔式胸腔鏡手術vsロボット支援下胸腔鏡手術
- (一社)日本胸部外科学会, Oct. 2025, 日本胸部外科学会定期学術集会, 78回, LOP14 - 6, Japanese低侵襲手術と開胸手術の両立を目指した若手外科医への手術手技教育に対する取り組み
- 日本気胸・嚢胞性肺疾患学会, Aug. 2025, 日本気胸・嚢胞性肺疾患学会雑誌, 25(2) (2), 72 - 72, Japanese女性気胸の定義 当科における月経随伴性気胸に対する治療戦略
- (NPO)日本肺癌学会, Jun. 2025, 肺癌, 65(3) (3), 211 - 212, Japanese
- (NPO)日本肺癌学会, Jun. 2025, 肺癌, 65(3) (3), 215 - 215, Japanese
- (一社)日本外科学会, Apr. 2025, 日本外科学会定期学術集会抄録集, 125回, PD - 6, Japaneseさらなる低侵襲を目指したロボット手術 ConsolerとBedside SurgeonによるUniportal fused RATS(Consoler and bedside surgeon fused Uniportal RATS)
- (NPO)日本気管食道科学会, Apr. 2025, 日本気管食道科学会会報, 76(2) (2), s38 - s38, Japanese
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), PD1 - 2, Japanese低侵襲手術のゆく先 当科におけるhinotori手術導入の初期成績
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), O35 - 6, Japanese隣接臓器合併切除を伴う胸腺腫手術の治療成績の検討
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), O49 - 2, JapaneseConsoler and Bedside surgeon fused RATSにおける出血トラブルシューティング
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), O52 - 3, Japanese胸腔鏡手術における新しい創部プロテクターの開発
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), P1 - 4, Japanese局所進行肺癌に対するSalvage手術の検討
- (一社)日本呼吸器外科学会, Apr. 2025, 日本呼吸器外科学会雑誌, 39(3) (3), P8 - 10, Japanese切除可能臨床病期2-3期非小細胞肺癌に対する術前化学療法の有効性
- (NPO)日本肺癌学会, Dec. 2024, 肺癌, 64(7) (7), 958 - 958, Japanese
- (一社)日本胸部外科学会, Nov. 2024, 日本胸部外科学会定期学術集会, 77回, LWS5 - 3, Japanese難治性気胸 難治性気胸に対する当科での手術戦略
- (一社)日本胸部外科学会, Nov. 2024, 日本胸部外科学会定期学術集会, 77回, LDB1 - 1, Japanese胸壁悪性腫瘍の外科治療 胸壁浸潤肺癌に対する術前補助療法の有用性
- (NPO)日本肺癌学会, Oct. 2024, 肺癌, 64(5) (5), 413 - 413, Japanese
- (NPO)日本肺癌学会, Oct. 2024, 肺癌, 64(5) (5), 449 - 449, Japanese
- (NPO)日本肺癌学会, Oct. 2024, 肺癌, 64(5) (5), 483 - 483, Japanese
- (NPO)日本肺癌学会, Oct. 2024, 肺癌, 64(5) (5), 569 - 569, Japanese
- 日本気胸・嚢胞性肺疾患学会, Aug. 2024, 日本気胸・嚢胞性肺疾患学会雑誌, 24(2) (2), 72 - 72, Japanese若年者気胸 若年者自然気胸に対する当科の手術戦略
- (NPO)日本肺癌学会, Oct. 2021, 肺癌, 61(6) (6), 510 - 510, Japanese
- (一社)日本胸部外科学会, Oct. 2020, 日本胸部外科学会定期学術集会, 73回, LOO16 - 2, Japanese
- (一社)日本外科学会, Aug. 2020, 日本外科学会定期学術集会抄録集, 120回, SF - 6, Japanese3DCTクラスター肺気腫評価に基づく肺癌術後呼吸器合併症予測
- (一社)日本呼吸器外科学会, Aug. 2020, 日本呼吸器外科学会雑誌, 34(3) (3), S - 1, Japanese肺移植から学ぶ呼吸器外科学 新しい肺保存法の開発、Ex Vivo Lung Perfusionの応用から紡ぐ呼吸器外科学の発展
- (一社)日本呼吸器外科学会, Aug. 2020, 日本呼吸器外科学会雑誌, 34(3) (3), RO21 - 2, JapanesecN0左上葉肺癌に対するマージンを意識した左上区切除 左上葉切除との比較
- (一社)日本呼吸器外科学会, Aug. 2020, 日本呼吸器外科学会雑誌, 34(3) (3), O7 - 1, Japanese病理学的胸膜浸潤を有する肺癌と洗浄胸水細胞診の関連についての検討
- (一社)日本呼吸器外科学会, Aug. 2020, 日本呼吸器外科学会雑誌, 34(3) (3), O16 - 5, JapaneseCOPD合併肺癌手術症例において術後の気管支拡張吸入薬の継続により得られる効果
- (一社)日本呼吸器外科学会, Aug. 2020, 日本呼吸器外科学会雑誌, 34(3) (3), MO15 - 9, Japanese神経内分泌マーカーの染色パターンによる肺大細胞神経内分泌肺癌の分類
- (株)南江堂, Dec. 2019, 胸部外科, 72(13) (13), 1068 - 1071, Japanese
- (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 697 - 697, Japanese
- (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 713 - 713, Japanese
- (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 716 - 716, Japanese
- (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 746 - 746, Japanese
- (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 964 - 964, Japanese
- (株)南江堂, Aug. 2019, 胸部外科, 72(8) (8), 570 - 573, Japanese
- (NPO)日本肺癌学会, Apr. 2019, 肺癌, 59(2) (2), 199 - 199, Japanese左後縦隔原発傍神経節腫の1切除例
- (一社)日本外科学会, Apr. 2019, 日本外科学会定期学術集会抄録集, 119回, SF - 7, Japanese胸腔鏡下肺区域切除後の術後呼吸機能変化
- (一社)日本呼吸器外科学会, Apr. 2019, 日本呼吸器外科学会雑誌, 33(3) (3), P59 - 7, Japanese80歳以上の高齢者非小細胞肺癌患者に対する縮小手術の検討
- (一社)日本呼吸器外科学会, Apr. 2019, 日本呼吸器外科学会雑誌, 33(3) (3), P66 - 1, Japanese肺腺癌切除例における浸潤性粘液性腺癌の臨床的意義
- (一社)日本呼吸器外科学会, Apr. 2019, 日本呼吸器外科学会雑誌, 33(3) (3), P105 - 4, Japanese胸腔鏡手術におけるICG蛍光法の使用経験
- (NPO)日本肺癌学会, Oct. 2018, 肺癌, 58(5) (5), 377 - 377, Japanese肺原発横紋筋肉腫の1切除例
- (NPO)日本肺癌学会, Oct. 2018, 肺癌, 58(6) (6), 455 - 455, Japanese
- (NPO)日本肺癌学会, Oct. 2018, 肺癌, 58(6) (6), 591 - 591, Japanese
- (NPO)日本肺癌学会, Apr. 2018, 肺癌, 58(2) (2), 150 - 151, Japanese胸腺類基底細胞癌の1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), RO7 - 1, Japanese癌細胞株と3次元in vitroモデルを応用した癌浸潤における候補遺伝子の解明
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), V3 - 2, Japanese気管分岐部切除を伴う左肺全摘術にPCPSが有用であった1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), V6 - 5, JapaneseSVC再建が必要な縦隔腫瘍切除において簡便な一時シャントが有用であった1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), V9 - 3, Japanese肺膿瘍部に対する広範なドレーン損傷による有瘻性膿胸に対し集学的治療が奏功した1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), V18 - 1, Japanese浸潤型胸腺腫の切除後の再発に対しreverse hockey stick incisionにて切除を行った1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), O13 - 4, Japanese胸腔鏡下手術における胸腔内高度癒着症例に対する当院での取り組み
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), O19 - 1, Japanese早期肺腺癌におけるPsf3(GINS3)の発現とUFTの有効性についての検討
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P28 - 2, Japanese開窓術を要した難治性膿胸の治療戦略について
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P32 - 3, Japanese悪性腫瘍との鑑別を要した肺ヒストプラズマ症の一例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P36 - 1, Japanese当院におけるびまん性肺疾患に対する胸腔鏡下肺生検の検討
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P44 - 7, Japanese肺血管処理における自動縫合器の適正使用についての検討
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P64 - 5, Japanese縦隔内異所性副甲状腺腫に対し縦隔腫瘍摘除術を行った2例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P67 - 6, Japanese転移性肺腫瘍との鑑別に苦慮した肺芽腫の1例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P71 - 8, JapaneseOccult縦隔リンパ節転移を生じたROS1融合遺伝子陽性PD-L1強陽性肺腺癌の切除例
- (一社)日本呼吸器外科学会, Apr. 2018, 日本呼吸器外科学会雑誌, 32(3) (3), P91 - 3, Japanese術後横隔神経麻痺に対する胸腔鏡下横隔膜縫縮術の検討
- (一社)日本呼吸器内視鏡学会, Jan. 2018, 気管支学, 40(1) (1), 81 - 81, Japanese
- (NPO)日本肺癌学会, Dec. 2017, 肺癌, 57(7) (7), 892 - 892, Japanese嚢胞内に発生した胸腺原発類基底細胞癌の1例
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 409 - 409, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 410 - 410, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 429 - 429, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 564 - 564, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 568 - 568, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 577 - 577, Japanese
- (NPO)日本肺癌学会, Sep. 2017, 肺癌, 57(5) (5), 577 - 577, Japanese
- (一社)日本サイトメトリー学会, Jun. 2017, Cytometry Research, 27(Suppl.) (Suppl.), 36 - 36, JapaneseiPS細胞を巡る最新の動向と今後の研究展開 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究
- (NPO)日本肺癌学会, Jun. 2017, 肺癌, 57(3) (3), 252 - 252, Japanese縦隔原発骨外性骨肉腫の1例
- (一社)日本組織培養学会, May 2017, 組織培養研究, 36(3) (3), 86 - 86, Japaneseリプログラミングを応用したがん幹細胞研究 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), O18 - 3, Japanese人工肺癌幹細胞による、肺癌組織再構築の試み
- (NPO)日本気管食道科学会, Apr. 2017, 日本気管食道科学会会報, 68(2) (2), s20 - s20, Japanese
- (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, PS - 6, Japanese早期肺腺癌におけるPsf3(GINS3)の発現の意義 組織マイクロアレイを用いたI期症例538例の検討
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), O10 - 2, Japanese続発性気胸に対する手術症例の検討
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), O14 - 6, Japanese胸腺腫に関連した新規疾患概念、抗PIT-1抗体症候群
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), O19 - 3, Japanese完全鏡視下手術手技を用いた拡大手術についての検討
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), P68 - 6, Japanese外科的切除によって著明な改善を認めた胸壁発生の腫瘍性低リン血症性骨軟化症の一例
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), P37 - 1, JapaneseVolume reductionにて症状が改善した縦隔原発骨外性骨肉腫の1例
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), P71 - 4, Japanese術後横隔神経麻痺に対する横隔膜縫縮術の検討
- (一社)日本呼吸器外科学会, Apr. 2017, 日本呼吸器外科学会雑誌, 31(3) (3), P103 - 6, Japanese血液透析患者に対する原発性肺癌手術症例の検討
- 兵庫県外科医会, Mar. 2017, 兵庫県外科医会会誌, 51, 3 - 16, Japanese
- (NPO)日本気管食道科学会, Feb. 2017, 日本気管食道科学会会報, 68(1) (1), 40 - 45, Japanese
- (NPO)日本肺癌学会, Dec. 2016, 肺癌, 56(7) (7), 1075 - 1076, Japanese肺結節切除標本にびまん性特発性神経内分泌細胞過形成を認めた1例
- (NPO)日本肺癌学会, Dec. 2016, 肺癌, 56(7) (7), 1076 - 1076, Japanese肺静脈内血栓を疑われた肺内発生神経内神経線維腫の1手術例
- (NPO)日本肺癌学会, Dec. 2016, 肺癌, 56(7) (7), 1077 - 1078, Japanese悪性黒色腫の肺転移と思われた1例
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 503 - 503, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 546 - 546, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 548 - 548, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 590 - 590, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 717 - 717, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 779 - 779, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 842 - 842, Japanese
- (NPO)日本肺癌学会, Nov. 2016, 肺癌, 56(6) (6), 862 - 862, Japanese
- (NPO)日本気管食道科学会, Apr. 2016, 日本気管食道科学会会報, 67(2) (2), s31 - s31, Japanese
- (NPO)日本肺癌学会, Apr. 2016, 肺癌, 56(2) (2), 138 - 138, Japanese病理組織診断で大細胞神経内分泌癌の中咽頭転移が判明した1例
- (一社)日本外科学会, Apr. 2016, 日本外科学会定期学術集会抄録集, 116回, OP - 3, Japanese肺癌におけるDNA Helicase蛋白複合体のバイオマーカーおよび分子標的としての有用性の検討
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), RO1 - 1, Japanese1cm以下微小肺癌切除例の検討
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), RO1 - 7, JapanesepT1N1非小細胞癌切除例におけるリンパ節病変の進展と予後に関する検討
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), V8 - 1, Japanese右鎖骨下動脈再建を要した肺尖部胸壁浸潤癌の1切除例
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), P62 - 5, Japanese周術期に感染性大動脈瘤を合併した降下性壊死性縦隔炎の1手術例
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), P73 - 3, Japanese外傷性肺嚢胞に対して緊急手術を要した1例
- (一社)日本呼吸器外科学会, Apr. 2016, 日本呼吸器外科学会雑誌, 30(3) (3), P76 - 4, Japanese体細胞初期化因子導入による肺癌幹細胞誘導
- (NPO)日本肺癌学会, Oct. 2015, 肺癌, 55(5) (5), 409 - 409, Japanese
- (NPO)日本肺癌学会, Oct. 2015, 肺癌, 55(5) (5), 411 - 411, Japanese
- (NPO)日本肺癌学会, Oct. 2015, 肺癌, 55(5) (5), 524 - 524, Japanese
- (NPO)日本肺癌学会, Oct. 2015, 肺癌, 55(5) (5), 564 - 564, Japanese
- (NPO)日本肺癌学会, Aug. 2015, 肺癌, 55(4) (4), 317 - 317, Japanese肺炎症性偽腫瘍の1切除例
- (NPO)日本肺癌学会, Aug. 2015, 肺癌, 55(4) (4), 317 - 317, Japanese肺癌と鑑別を要した炎症性結節の1例
- (株)南江堂, Jul. 2015, 胸部外科, 68(7) (7), 546 - 549, Japanese
- 日本気胸・嚢胞性肺疾患学会, Jul. 2015, 日本気胸・嚢胞性肺疾患学会雑誌, 15(1) (1), 61 - 61, Japanese自然気胸に対するx Gateの使用経験
- (NPO)日本気管食道科学会, Apr. 2015, 日本気管食道科学会会報, 66(2) (2), s25 - s25, Japanese気道狭窄をきたした食道神経鞘腫の1例
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), O26 - 5, Japanese肺切除後の脳梗塞に対し血栓回収療法を行い良好な経過を得た1例
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), O36 - 6, Japanese第2癌を念頭においた第1癌に対する区域切除術の検討
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), O56 - 1, Japanese肺腺癌におけるCHFR(Checkpoint protein with forkhead and ring finger domain)発現の意義
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), V16 - 1, Japanese酸化セルロースシートの止血効果を利用した胸腔鏡手術の工夫
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), V29 - 6, Japanese胸腔鏡手術における血管損傷の危険因子の検討
- (一社)日本呼吸器外科学会, Apr. 2015, 日本呼吸器外科学会雑誌, 29(3) (3), P53 - 8, Japanese抗NMDA受容体脳炎を伴った縦隔奇形腫の1手術例
- 医学図書出版(株), Dec. 2014, ICUとCCU, 38(12) (12), 842 - 843, Japanese
- (一社)日本癌学会, Sep. 2014, 日本癌学会総会記事, 73回, P - 3096, English非小細胞肺癌におけるPsf3の役割について(The role of Psf3 expressions in non-small-cell carcinoma)
- 日本気胸・嚢胞性肺疾患学会, Aug. 2014, 日本気胸・嚢胞性肺疾患学会雑誌, 14(2) (2), 159 - 159, Japanesevon Willebrand's Diseaseを基礎疾患にもつ血気胸手術の1例
- 日本気胸・嚢胞性肺疾患学会, Aug. 2014, 日本気胸・嚢胞性肺疾患学会雑誌, 14(2) (2), 162 - 162, Japanese胸腔鏡下自然気胸手術をより確実なものにするためのダブルレイヤー法の検討
- (NPO)日本肺癌学会, Aug. 2014, 肺癌, 54(4) (4), 243 - 243, Japanese腸型が疑われた肺腺癌の1例
- (一社)日本呼吸器外科学会, Apr. 2014, 日本呼吸器外科学会雑誌, 28(3) (3), RS3 - 1, JapaneseCTでの肺容積測定による術後肺機能評価
- (一社)日本呼吸器外科学会, Apr. 2014, 日本呼吸器外科学会雑誌, 28(3) (3), V15 - 4, Japanese完全鏡視下で肺葉切除後の気管支断端被覆術の工夫
- (一社)日本呼吸器外科学会, Apr. 2014, 日本呼吸器外科学会雑誌, 28(3) (3), 1 - 6, Japanese肺癌術後乾性咳嗽に対するトシル酸スプラタストの有用性の検討
- (一社)日本呼吸器外科学会, Apr. 2014, 日本呼吸器外科学会雑誌, 28(3) (3), 1 - 5, Japanese高齢者肺葉切除症例のearly outcomeについて
- (NPO)日本肺癌学会, Apr. 2014, 肺癌, 54(2) (2), 89 - 89, Japanese臍帯血移植前の消失しない肺浸潤影に対して胸腔鏡下肺葉切除を施行した1例
- (一社)日本外科学会, Mar. 2014, 日本外科学会雑誌, 115(臨増2) (臨増2), 435 - 435, Japanese
- (一社)日本外科学会, Mar. 2014, 日本外科学会雑誌, 115(臨増2) (臨増2), 639 - 639, Japanese
- (一社)日本内視鏡外科学会, Nov. 2013, 日本内視鏡外科学会雑誌, 18(7) (7), 512 - 512, Japanese完全鏡視下肺葉切除術における術後合併症、術後補助化学療法の忍容性について 開胸手術との比較
- (NPO)日本肺癌学会, Oct. 2013, 肺癌, 53(5) (5), 479 - 479, Japanese
- (一社)日本呼吸器外科学会, Apr. 2013, 日本呼吸器外科学会雑誌, 27(3) (3), 377 - 377, Japanese80歳以上の高齢者肺癌の手術症例の検討
- (一社)日本呼吸器外科学会, Apr. 2013, 日本呼吸器外科学会雑誌, 27(3) (3), V11 - 06, Japanese区域間静脈を指標とする肺門側からの剥離を重視した胸腔鏡下右S2区域切除術
- (一社)日本呼吸器外科学会, Apr. 2013, 日本呼吸器外科学会雑誌, 27(3) (3), P39 - 01, Japanese術直後に腎梗塞を発症した粘液産生性腺癌の1手術例
- (一社)日本呼吸器外科学会, Apr. 2013, 日本呼吸器外科学会雑誌, 27(3) (3), P71 - 10, Japanese気管支上皮内に広範なpagetoid spraredを呈した大細胞神経内分泌癌(LCNEC)の1例
- (一社)日本内視鏡外科学会, Dec. 2012, 日本内視鏡外科学会雑誌, 17(7) (7), 365 - 365, JapaneseComplete VATS Segmentectomyの手術成績 鏡視下手術の視覚的利点を活かした術式の工夫
- (NPO)日本肺癌学会, Dec. 2012, 肺癌, 52(7) (7), 1084 - 1084, Japanese筋上皮への分化を伴い特異な組織像を呈した原発性肺癌の1例
- (NPO)日本肺癌学会, Oct. 2012, 肺癌, 52(5) (5), 578 - 578, Japanese
- (NPO)日本肺癌学会, Oct. 2012, 肺癌, 52(5) (5), 810 - 810, Japanese
- (一社)日本呼吸器外科学会, Apr. 2012, 日本呼吸器外科学会雑誌, 26(3) (3), O12 - 04, Japanese心大血管疾患を同時期に合併した原発性肺癌に対する外科治療例の検討
- (一社)日本呼吸器外科学会, Apr. 2012, 日本呼吸器外科学会雑誌, 26(3) (3), P07 - 04, Japanese肺癌切除症例における気管支形成術の検討
- (一社)日本呼吸器外科学会, Apr. 2012, 日本呼吸器外科学会雑誌, 26(3) (3), P07 - 09, Japanese胸壁浸潤非小細胞肺癌切除についての検討
- (一社)日本呼吸器外科学会, Apr. 2012, 日本呼吸器外科学会雑誌, 26(3) (3), P09 - 09, Japanese肺癌術後の2次性肺腫瘍に対する手術検討
- (一社)日本外科学会, Mar. 2012, 日本外科学会雑誌, 113(臨増2) (臨増2), 802 - 802, Japanese
- (NPO)日本肺癌学会, Oct. 2011, 肺癌, 51(5) (5), 426 - 426, Japanese
- (一社)日本外科学会, May 2011, 日本外科学会雑誌, 112(臨増1-2) (臨増1-2), 364 - 364, Japanese
- (NPO)日本肺癌学会, Apr. 2011, 肺癌, 51(2) (2), 148 - 148, Japanese前縦隔原発の脱分化型脂肪肉腫の1例
- (一社)日本呼吸器外科学会, Apr. 2011, 日本呼吸器外科学会雑誌, 25(3) (3), O14 - 06, Japanese非小細胞癌完全切除例におけるextranodalリンパ節転移の意義
- (一社)日本呼吸器外科学会, Apr. 2011, 日本呼吸器外科学会雑誌, 25(3) (3), P66 - 07, Japanese前縦隔に発生した脱分化型脂肪肉腫の1切除例
- (NPO)日本肺癌学会, Oct. 2010, 肺癌, 50(5) (5), 513 - 513, Japanese
- (NPO)日本肺癌学会, Oct. 2010, 肺癌, 50(5) (5), 534 - 534, Japanese
- (NPO)日本肺癌学会, Oct. 2010, 肺癌, 50(5) (5), 552 - 552, Japanese
- (NPO)日本肺癌学会, Oct. 2010, 肺癌, 50(5) (5), 652 - 652, Japanese
- (NPO)日本肺癌学会, Aug. 2010, 肺癌, 50(4) (4), 402 - 402, Japanese胸腺発生大細胞神経内分泌癌(LCNEC)の1例
- (一財)住友病院, Jul. 2010, 住友病院医学雑誌, (37) (37), 69 - 69, JapaneseCTガイド下肺生検中に空気塞栓症を生じた1例
■ Lectures, oral presentations, etc.
- 肺癌, Nov. 2025, Japanese, (NPO)日本肺癌学会臨床病期I期Micropapillary componentを有するSTAS陽性非小細胞肺癌の臨床病理学的特徴Oral presentation
- 肺癌, Oct. 2025, Japanese, (NPO)日本肺癌学会当院における術前導入免疫治療の使用経験Oral presentation
- 日本外科学会定期学術集会抄録集, Apr. 2025, Japanese, (一社)日本外科学会再生医療と外科 肺組織修復を目的とした,豚肺へのオルガノイド移植法の検討Public symposium
- 日本呼吸器外科学会雑誌, Apr. 2025, Japanese, (一社)日本呼吸器外科学会臨床病期I期solidな陰影の非小細胞肺癌 男女間で性質に違いがあるのか?
- 25th World Conference on Lung Cancer., Sep. 2024, EnglishDifferentiation and Metabolic Phenotypes of Lung Squamous Cell Carcinoma Organoids are Modified by the Tumor Microenvironments.Poster presentation
- 日本呼吸器外科学会雑誌, Apr. 2024, English, (一社)日本呼吸器外科学会EBUS-TBNAサンプルからの肺がんオルガノイドの確立(Establishment of lung cancer organoid from EBUS-TBNA samples)
- International Thoracic Surgical Oncology Summit 2023, Sep. 2023, EnglishOptimization of Lung Cancer Organoids Orthotopic Injection Method in Mice.Poster presentation
- 103rd AATS Annual Meeting, May 2023, EnglishPatient derived xenograft engraftment associated with radiological findings in lung adenocarcinomas.Oral presentation
- 肺癌, Nov. 2019, Japanese, (NPO)日本肺癌学会DLL3の発現は、LCNECに対する術後補助化学療法の効果の指標になる
- 20th World Conference on Lung Cancer, Sep. 2019, EnglishDLL3 is a predictive marker of sensitivity to adjuvant chemotherapy for high-grade neuroendocrine tumors.Poster presentation
- 日本呼吸器外科学会雑誌, Apr. 2019, Japanese, (一社)日本呼吸器外科学会術前HbA1c値が、肺腺癌術後再発に与える影響
- 肺癌, Oct. 2018, Japanese, (NPO)日本肺癌学会病理病期I期高悪性度神経内分泌癌の臨床病理学的検討
- Sep. 2018, EnglishEfficacy of perioperative chemotherapy for high-grade neuroendocrine tumors. 19th World Conference on Lung Cancer.Poster presentation
- 日本呼吸器外科学会雑誌, Apr. 2018, Japanese, (一社)日本呼吸器外科学会IL-6 signalの阻害は、肺癌幹細胞を標的にした新規治療法になりうるか
- 肺癌, Sep. 2017, Japanese, (NPO)日本肺癌学会人工肺癌幹細胞を用いた、肺癌組織再構築と新規治療法開発の試み
- American Association for Cancer Research Annual Meeting 2017, Apr. 2017, EnglishInterleukin-6 blockade, a novel cancer stem cell targeted therapy, attenuates lung cancer tissue construction.Poster presentation
- 日本外科学会雑誌, Mar. 2014, Japanese, (一社)日本外科学会本邦におけるNET治療の実態 診療ガイドラインへの展開 肺神経内分泌癌に対する手術症例の臨床的検討
- 肺癌, Oct. 2013, Japanese, (NPO)日本肺癌学会大細胞神経内分泌癌の診断と治療方針 高悪性度神経内分泌癌に対する手術症例の臨床的検討
- 15th World Conference on Lung Cancer., Oct. 2013, EnglishEfficacy of adjuvant chemotherapy for lung adenocarcinoma patients with pleural lavage cytology positive findings.Oral presentation
- 肺癌, Oct. 2012, Japanese, (NPO)日本肺癌学会洗浄胸水細胞診陽性肺腺癌に対する術後補助化学療法の検討
- 日本外科学会雑誌, Mar. 2012, Japanese, (一社)日本外科学会小型肺癌に対する治療戦略 cT1bN0M0肺腺癌及び扁平上皮癌に対する区域切除術の検討
- 肺癌, Oct. 2011, Japanese, (NPO)日本肺癌学会Pathological stage Iの大細胞神経内分泌癌(LCNEC)に対する術後補助化学療法の検討
- 日本呼吸器外科学会雑誌, Apr. 2011, Japanese, (一社)日本呼吸器外科学会大細胞神経内分泌癌(LCNEC)に対する補助化学療法とchemo sensitivityに関する検討